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ABSTRACT

Prostate cancer is the most common cancer diagnosed in men and the second
leading cause of cancer death among men in the United States. African-American men
have substantially higher prostate cancer incidence and mortality than EuropeanAmerican men. It is unclear whether this incidence is due to acquired DNA changes
(sporadic cancer) or if germline Mendelian genetics/genomics (inherited cancer) is the
source of this health disparity. To explore this cause, the focus of this dissertation paper
is family health history and hereditary prostate cancer. A family history tool is the most
commonly used predictive instrument for hereditary prostate cancer. The identification
of men with hereditary prostate cancer allows healthcare providers to identify high-risk
relatives who are more likely to benefit from targeted health promotion and cancer
prevention programs. Use of non-validated family history tools may prevent healthcare
providers from collecting information needed to identify hereditary prostate cancer and
ascertaining accurate risk assessment in unaffected African-American men. This pilot
study was conducted to validate the effectiveness of a family cancer history tool and
pedigree analysis in the identification of hereditary prostate cancer in a community based
sample of African-American men. While small sample size limited the power of the
analysis, the family history tool and pedigree analysis appears to have analytical validity
as a public health instrument for identifying hereditary prostate cancer. Twenty-two
percent (11 of 49) of consultands reported a personal history of prostate cancer with one
hereditary prostate cancer family observed. Age was significantly related to a personal
history of prostate cancer (p= 0.05) but other known predictors of prostate cancer were
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statistically undetectable. The pilot study demonstrated that though the family cancer
history tool appears to have clinical validity a larger sample is needed to prove clinical
validity. Additional research is needed to examine analytical validity, clinical utility and
ethical, legal and social issues surrounding the use of family cancer history and pedigree
analysis as a public health intervention for addressing the health disparity of prostate
cancer in African-American men

iii

DEDICATION

I dedicate my dissertation manuscript to my family for their unwavering support.
Thank you Calvin, my husband, for being mommy and daddy for the past three
years. Thank you for staying up late at night with me and catering to my every need.
Thank you for all the unplanned trips to Clemson. Most of all, thank you for your
continuous encouragement.
Thank you girls, Calin, Zaria and Alisa, for supporting mommy. Thank you for
the time and sacrifice you have made to let me do this. Thank you for continuing to do
your best in school, even though I was not there to help you. Thank you for being my
reason for not giving up.
Thank you Mom and Dad for your continued support and words of
encouragement. Thank you, Mom, for the many meals, picking up the girls, and keeping
house for me. Thank you, Dad, for helping Calvin with the yard and letting me borrow
your porch to get away from everything.
In memory of all of my family members I have lost to cancer during my
dissertation process.

I dedicate my doctoral career to understanding why African-

Americans are disproportionately burden with cancer:
Johnny Mac Rollinson (step father): October 8, 1951- March 28, 2009
Samuel Henry Belcher (grandfather): February 29, 1932- May 21, 2010
Lizzie Mae Coleman (grandmother): July 19, 1923- June 5, 2011

iv

ACKNOWLEDGMENTS
I would like to express my deep appreciation and gratitude to my dissertation
chair and mentor, Dr. Julia Eggert, for the patient guidance and mentorship she provided
to me throughout the program, but especially for the many hours she spent working with
me in preparing my manuscript and my oral defense. I can’t imagine the sacrifices Dr.
Eggert has made to direct the Healthcare Genetics Program; but, I will forever be
indebted to her for bringing me back to my first love, biology and genetics.
I would also like to thank my committee members, Dr. Elisabeth Chismak, Dr.
Chin Fu Chen, and Dr. Dewayne Moore, for the professional guidance, thoughtprovoking suggestions, and the general collegiality that each of them offered to me over
the years.
I would like to thank all the professors of the Clemson Nursing Department for
the contributions that each of them made to my intellectual growth during my years of
study at Clemson University. Finally, I would be remiss if I didn’t acknowledge Dr.
Rosanne Pruitt for her outstanding leadership of the Nursing Department. Thank you, Dr.
Pruitt, for the support and consideration you have given me over the years of my masters
and doctoral education.
I would like to thank all the church congregations and their respective ministers
that supported my research.

I render a special thanks to Mrs. Marian Robinson,

Community Liaison for the Clemson University Cooperative Extension Service, for
helping me with my data collection through her expert advice and connections.

v

TABLE OF CONTENTS
Page
TITLE PAGE ..................................................................................................................... i
ABSTRACT ....................................................................................................................... ii
DEDICATION ................................................................................................................... iv
ACKNOWLEDGMENTS ................................................................................................. v
LIST OF TABLES ... …………...………………………………………………………..viii
LIST OF FIGURES........................................................................................................... ix
CHAPTER
I. INTRODUCTION ..........................….……………………………………..….

1

ACCE Model ........................................................…………………………... 3
Concepts and Assumptions ............................................................................. 5
Conclusions ..................................................................................................... 10
References ....................................................................................................... 12
II. MANUSCRIPT I: THE ACCURACY AND RELIABILITY
OF A FAMILY CANCER HISTORY ASSESSMENT
IN PEDIGREE RESEARCH OF HEREDITARY
PRCA IN AFAMS ........................................................................................... 15
Abstract ..................................................................................................…….
Introduction ................................................................................….…………
Methods ...............................…………………….………..………………….
Results .............................……………………….………..………………….
Discussion ............................................................…………………………...
References .......................................................................................................

15
17
26
29
40
41

III. MANUSCRIPT II: PILOT TEST OF COMMUNITYBASED FAMILY HISTORY TOOL AND
PEDIGREE ANALYSIS TO PREDICT
HEREDITARY PROSTATE CANCER ......................................................... 46
Abstract ...........................................................................................................
Introduction ....................................................................................….………
Materials and Methods ....................................................................................
Statistical Analysis ..........................................................................................

vi

46
47
50
56

Table of Contents (Continued)
Page
Results .............................................................................................................
Discussion ......................................................................................….………
Conclusion .......................................................................................................
Implications for Translational Research ..........................................................
References .......................................................................................................

57
61
64
64
67

IV. MANUSCRIPT III: USE OF FAMILY HISTORY IN
PUBLIC HEALTH NURSING TO IDENTIFY
AFRICAN-AMERICAN MEN AT RISK FOR
HEREDITARY PROSTATE CANCER: CASE
REPORT ........................................……….…………………….…………… 70
Abstract ...........................................................................................................
Introduction ....................................................................................….………
Case Report .....................................................................................................
Discussion .......................……………………….………..………………….
Implications for Nursing Practice ....................................................................
Inherited Genetic Risk Factors ........................................................................
Acquired Genetic/Genomic Injuries ................................................................
Prostate Cancer (PrCa) in AfAm Men.............................................................
Conclusion .......................................................................................................
References .......................................................................................................

70
71
72
74
77
77
81
84
87
87

V. SUMMARY AND CONCLUSIONS……….…………………….…………… 92
Summary.......................................................................................................... 92
Conclusions ..................................................................................................... 93
References ....................................................................................................... 94
APPENDICES ................................................................................................................. 95
A.
B.
C.
D.
E.
F.
G.

Common Genetic Terms Used Throughout Manuscript .................................... 96
Family History Tool and Demographic Form .................................................... 98
Dissertation Research/Recruitment Contact Form .............................................104
IRB Approval Letter ...........................................................................................106
IRB Information Letter .......................................................................................108
Authorization for Release of Protected Health Information ...............................111
South Carolina Central Cancer Registry Statistics
Fee Waiver.......................................................................................................112
H. Discovering History Education Workshop Presentation
Documents .......................................................................................................115
I. Clemson University Healthcare Genetics Toolkit. .............................................116

vii

LIST OF TABLES

Table

Page

1.1.

Prevalence, Morbidity Incidence, Mortality ..........................................................

2.1.

Questions for Assessing Literate using ACCE Domains ...................................... 19

2.2.

Selection of Studies ............................................................................................... 27

2.3.

Literature Review Article by ACCE Domain ........................................................ 29

3.1.

Participating Churches........................................................................................... 52

3.2.

Consultant Demographics ..................................................................................... 58

3.3.

Percentage of Sample Reporting Family History of Cancer.................................. 58

3.4.

Chi-Square (χ2) and p-values for Predictor Variables ........................................... 58

3.5.

Chi-Square (χ2) and p-values for each (categorical)
Predictor Variable ............................................................................................. 59

3.6.

Regression Analysis for Select Predictor Variables .............................................. 60

4.1.

Healthy People 2020 Objectives Related to Family History
and Genetic Tests .............................................................................................. 76

viii

6

LIST OF FIGURES

Figure

Page

1.1.

ACCE Model .........................................................................................................

4

1.2.

SEER data of Age-Specific Incidence Rates by Race/Ethnicity ...........................

7

3.1.

Education Program and Family History Study Model........................................... 53

3.2.

Personal History of PrCa ....................................................................................... 65

3.3.

National (SEER), State (SCCCR), Discovering History
Comparison of Age at Diagnosis ...................................................................... 66

4.1.

Hereditary Prostate Cancer Pedigree ..................................................................... 74

ix

CHAPTER I
INTRODUCTION

In the United States (US), the incidence rate of prostate cancer (PrCa) in AfricanAmerican (AfAm) males is nearly double that of European-American (EuAm) males.
More significant, is the more than double mortality rate due to PrCa between AfAms and
EuAms. According to Surveillance Epidemiology and End Results Statistical (SEER)
Facts Sheets, the mortality rate for AfAm is 53.1 per 100,000 men compared to EuAm at
21.7 per 100,000 men (Howlander et al., 2012). Higher incidences of PrCa, the migration
of initial diagnosis at younger ages, and more aggressive disease at earlier ages in AfAm
men, imply a genetic predisposition to the malignancy (Mastalski, Coups, Ruth, Raysor,
& Giri, 2008; Nieder, Taneja, Zeegers, & Ostrer, 2003).
PrCa is a malignancy with a multifactorial and polygenic etiology (Witte, 2009).
Seventy-five percent of the total PrCa cases are due to sporadic, or somatic mutations,
15-20% are due to a combination of environment and inherited genetic susceptibility and
5-10% are due to highly penetrant, germ-line mutations (National Cancer Institute (NCI),
2012). While genetic scientists continue to search for the specific genotypes, family
history and pedigree analysis are being used by researchers to identify families with the
phenotype labeled as hereditary PrCa (Bratt, 2002). Hereditary PrCa is the focus of this
research; specifically the translatability of comprehensive family history and pedigree
analysis to first identify and eventually assess the presence of this risk in the AfAm male
population.
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The objective for this dissertation research is to examine the feasibility for use of
comprehensive family history and pedigree analysis, in the public health setting, to
facilitate identification of AfAm men with hereditary prostate cancer. The specific aims
used to meet this objective are the following:

1. Identify families with hereditary PrCa and confirm personal history of PrCa.
a. Use the Hopkins Criteria of hereditary PrCa as defined by Carter et al.
(1992) and as utilized in genetic research of PrCa to identify pedigrees
with obvious Mendelian patterns of transmission of PrCa.
b. Determine the proportion of self-reported personal PrCa history that can
be confirmed through the South Carolina Central Cancer Registry
(SCCCR) that will serve as a method of identifying PrCa cases.
c. Identify the proportion of at risk individuals in each hereditary PrCa
family as these individuals are the target of public health educational
programs.
2. Identify variables in the piloted family cancer history tool that best predict
hereditary PrCa.
a. H0—There is no relationship between age and personal history of PrCa.
b. H0—There is no relationship between having a father with PrCa and a
personal history of PrCa
c. H0—There is no relationship between having a father with any cancer and
a personal history of PrCa.
d. H0—There is no relationship between having a brother with PrCa and a
personal history of PrCa.
e. H0—There is no relationship between having a brother with any cancer
and a personal history of PrCa.
f. H0—There is no relationship between having a sister with breast cancer
and a personal history of PrCa.
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g. H0—There is no relationship between having a mother with any cancer is
and a personal history of PrCa.
h. H0—There is no relationship between having multiple brothers with
cancer and a personal history of PrCa.
3. Evaluate the validity and utility of the piloted family cancer history tool and
pedigree analysis of hereditary PrCa as used in a pilot sample of southeastern
AfAm men. The assumption of this specific aim is that the family cancer risk
assessment model as evaluated using statistical analysis of family cancer
history data and pedigree analysis will find significant correlation between
known family history variables (age, brother with cancer, father with cancer,
multiple affected first degree relatives.)
a. H0—There is no relationship between known predictor variables of
hereditary PrCa and personal history of PrCa.
b. H0—There is no relationship between confounding variables (education,
health insurance, time spent outside during daytime hours) and a personal
history of PrCa.
The model, which refers to the four domains of the evaluation process; analytic
validity, clinical validity, clinical utility and associated ethical, legal, and social
implications, (ACCE) is used as the framework for review of the literature, study design,
and translation into clinical practice (Yoon, Scheuner, and Khoury, 2003). See Figure
1.1.

ACCE Model
Yoon et al. (2003) suggested the ACCE model to evaluate the validity and utility
of using family history as a tool for predicting risk of genetic disease. The ACCE model
was developed by the Centers for Disease Control and Prevention’s Office of Public
Health Genomics (OPHG) (Centers for Disease Control and Prevention, 2010). It was
the first publicly available analytical process for evaluating scientific data on emerging

3

The domains of the ACCE Model and the respective subdomains are used to evaluate genetic
testing for use in public health practice. Image from: http//www.cdc.gov/genomic.

Figure 1.1. ACCE Model.

genetic tests. According to Yoon, et al. (2003) family history can be used as a tool to
ascertain risk for common, heritable, chronic diseases and thereby identify individuals
with increased risk of disease susceptibility.

In an earlier article, Yoon, Scheuner,

Peterson-oehlke, Gwinn, Faucett, & Khoury (2002) state that:

Collection and interpretation of family history has rarely been applied to
the practice of preventive medicine to assess disease risk and influence
early detection and prevention strategies. In this setting, pedigree analysis
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has primarily been limited to rate cases of cancer or cardiovascular disease
where a strong genetic component is obvious. Even when there is a strong
family history, many of these high-risk people who could benefit from a
genetic evaluation are missed by their primary care physicians. (pp.305)

In order for a disease to be appropriate for a family history tool to be adapted in
public health settings, Yoon et al. (2003) noted the disease must be associated with a
substantial public health burden as assessed in terms of prevalence, morbidity and
mortality. As seen in Table 1.1 and Figure 1.2, AfAms are disproportionately affected
with PrCa. Additional criteria examined as part of the literature review include the
following: well-defined case definition, awareness of disease among relatives, accurate
reports by family members, and family history as an established risk factor. Criteria not
examined in the review but still significant are associated disabilities, healthcare costs,
and effective interventions for primary and secondary prevention.

Concepts and Assumptions
This section defines reoccurring terms and concepts for this research effort. The
first term is African-American.

African-American (AfAm)
For the purpose of this manuscript, the definition of AfAm will incorporate the
description published by Agyemang, Bhopal, and Bruijnzeels (2005). These authors
note:
The term AfAm refers to a person of African ancestral origins who self
identifies or is identified by others as AfAm. While the term AfAm has
been used at least since the 1920s, it has been the preferred term in the
USA since the 1970s. As most AfAms in the USA originated from sub-
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Table 1.1. Prevalence, Morbidity, Incidence, Mortality.
Criteria
Prevalence

Statistics
Complete Prevalence
White—1,984,603
Black—284,208

Morbidity

5 Year Survival Rate For Men diagnosed in 2003
White—99.9
Black—97.5

Incidence

Age-Adjusted U. S. Incidence Rates 2004-2008 per 100,000
White—149.5
Black—233.8

Mortality

Age-Adjusted U. S. Mortality Rates 2008 per 100,000
White—22.4
Black—54.9

Table based on SEER incidence and NCHS mortality statistics. Most can be found
within: Howlander, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Waldron,
W., Alterkruse, S. F., Kosary, C. L., Ruhl, J. Tatalovich, Z., Cho, H., Mariotto, A.,
Eisner, M. P. Lewis, D. R. Chen, H. S., Feur, E. J., Cronin, K. A., Edwards, B. K (eds).
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD,
http://seer.cancer.gove/csr/1975_2008/, based on November 2010 SEER data submission,
posted to the SEER web sit, 2011.
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Table from Cancer Statistics: Fast Stats http://seer.cancer.gov/faststats/selections.php
Figure 1.2. SEER data of Age-Specific Incidence Rates by Race/Ethnicity.

7

Saharan Africa, the term is not applied to Africans from northern Africancountries such as Morocco. Most AfAms are descendants of persons
brought to the Americas as slaves between the 17th and 19th century
(distant ancestry). Such people differ from others who came from Africa
or the Caribbean in the 20th and 21st centuries (recent ancestry), in terms
of culture, language, migration history, and health (Agyemang et al., 2005,
pp. 1016).

Family and Family Health History
From the paradigm of healthcare genetics, family is defined as biologically related
individuals sharing common genetic information, such as genes, allelic variants and
frequencies due to a common ancestor. Family can be further characterized by parental
lineage (maternal or paternal side of the family) and degree of relatedness (first- degreeparent, siblings, children; second degree- aunts, uncles, grandparents, nieces, and
nephews). The family structure is dynamic in that it continually changes due to marriage,
divorce, adoption, birth and death.

The concept of family is also complex as it is

influenced by beliefs about inheritance, cultural practices, political and socioeconomic
factors, i.e., half-siblings, stepparents, same sex marriage, consanguinity, co-habitation,
and polygamy (McBrath and Edwards, 2009).
The family health history describes the disease history of relatives and identifies
potential genetic relationships. In order to estimate an individual’s hereditary cancer risk,
it is essential to summarize family cancer history information in the form of a pedigree
(National Cancer Institute, 2012).
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Pedigree
A medical pedigree is a standardized diagrammatic presentation of family
relationships in which patterns of disease transmission are tracked. The diagrammatic
illustration facilitates the depiction of a family’s health history and genetic relationships
(Bennett, French, Resta, & Doyle, 2008).
Pedigrees used specifically for risk assessment should include a minimum of 3
complete generations (Murff, Spigel, & Syngal, 2004). The pedigree should contain
information such as age or year of birth, age and cause of death, ethnic background of
each grandparent, the status of each relative as affected or unaffected, age at disease
onset, and other pertinent healthcare information (Bennett et al, 2008). Hereditary PrCa
is indicated if the pedigree reveals: multiple PrCa in close relatives, early age of onset (<
55 years), and recognizable Mendelian inheritance pattern (Carter, Beaty, Steinberg,
Childs, & Walsh, 1992.)

Hereditary PrCa
In 1992, Carter used family history to define hereditary PrCa. An individual was
considered as being at risk for hereditary PrCa if his family history revealed PrCa in the
following areas:

Three or more first-degree relatives (father, brother, son).
Three successive generations of either the maternal or paternal lineages
(Mendelian pattern of inheritance).
At least two relatives affected at or before the age of 55 years.
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Whereas men with familial PrCa also had a positive family history, it was weakly
positive and insufficient to satisfy the hereditary PrCa criteria. Patients with no known
family history were considered to have acquired or sporadically induced PrCa (Carter et
al., 1992). In a study of the clinical impact of different definitions of hereditary PrCa,
Sacco, et al., (2005) simplified the definitions as: “Sporadic PrCa is cancer occurring
randomly in the population; familial PrCa is unpredictable clustering of PrCa in families;
and, hereditary PrCa is a strong clustering and early onset of PrCa.” pp. 762.
Carter et al. (1992) concluded that 43% of early age onset PrCa (disease onset
<55 years of age) was due to autosomal dominant inheritance of a rare allele. More
importantly, it was noted that early age onset hereditary PrCa constituted only a small
proportion (9% by age 85) of all PrCa occurrence. The results of this study found that
only 2% of PrCa in US Caucasian men occurs in those aged less than 55. Finally, Carter,
et al. (1993) concluded that the impact of hereditary PrCa in the population is the greatest
at younger ages.

Conclusions
PrCa is a public health problem and a source of health disparity in AfAm
populations.

Health disparities adversely affect groups of people who have

systematically experienced greater obstacles to health based on but not limited to their
racial or ethnic groups, socioeconomic status, gender; age, cognitive ability, physical
ability, geographic location or other characteristics historically linked to discrimination or
exclusion (US Department of Health and Human Services, 2010).
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The first step to resolving any problem no matter the source of the problem is
awareness and acknowledgment of a problem. In the US, discussion of ethnicity/race
differences can make for a very sensitive and emotionally charged debate. In healthcare
genetics, ethnicity/race is a phenotype that must be considered when assessing risk of
malignancy and given just as much, if not more weight when assessing, considering
prognosis, and reoccurrence of malignancy. Though no sharp genetic boundaries can be
drawn between ethnically/racially diverse groups, there are variations in frequency of
certain polymorphisms and haplotypes within and among populations (Bonham,
Warshauer-Baker, & Collins, 2005). The discovery of such variations helps researchers
and clinicians to understand why AfAm men are disproportionately burdened with PrCa.
According to a recent Cancer Disparity Factsheet published by the National Cancer
Institute of the National Institute of Health (NIH), nearly all of the genetic variants
associated with an increased risk of developing PrCa were most often found in AfAm
men. Certain combinations of these polymorphisms are associated with a five-fold
increased risk of PrCa in AfAm men (National Cancer Institute, 2012).
The remainder of this document is comprised of three manuscripts. The first
manuscript is a systematic literature review, utilizing the ACCE model to examine the
literature to document the validity and utility of family history survey as a predictive test
for hereditary PrCa. The second manuscript details a feasibility study to evaluate the
clinical validity of a specific family history survey and pedigree analysis in a communitybased, sample of AfAm men in South Carolina, non-selected for family history status or
disease status. The third manuscript presents a case report illustrating the clinical utility
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of the piloted family history tool and pedigree analysis to identify and assess risk of
hereditary PrCa in a family with multiple cases of PrCa.

Together these three

manuscripts help to further define the phenotype of hereditary prostate cancer, present the
body of evidence related to family history and pedigree analysis as it relates to hereditary
PrCa. Finally, a case report will illustrate how the researcher envisions translation of
comprehensive family history and pedigree analysis of hereditary PrCa into public
healthcare.
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CHAPTER II
MANUSCRIPT I: THE ACCURACY AND RELIABILITY OF A FAMILY CANCER
HISTORY ASSESSMENT IN PEDIGREE RESEARCH OF HEREDITARY PRCA IN AFAMS

Abstract
Background
Family history survey is the most commonly used predictive instrument for
hereditary cancers, including PrCa. Early identification of African-American men with
hereditary PrCa is critical in order to promote health in men of high-risk families. This
manuscript presents a systematic review of 12 studies, which delineate the relationship
between family history and risk of hereditary prostate cancer.

Method
The domains of the ACCE model served as the framework for reviewing the
literature related to the utilization of family history as a public health nursing intervention
in African-American communities. The analytical and clinical validity of family history
relative to prostate cancer is strong but the evidence of the clinical utility is lacking.

Results
Eighteen articles were found that address one or more of the four domains of the
ACCE model. Of the eighteen articles, seven reported on cohort studies and 2 reported
on case control studies. Five articles addressed analytical validity of family history in
predicting prostate cancer. Two articles addressed clinical validity of family history and
prostate cancer. Five articles addressed the clinical utility of family history in improving
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healthcare outcomes related to prostate cancer. Eight articles addressed the ethical, legal
and social implications of family history and hereditary disorders, but not specific to
prostate cancer.

Conclusion
The analytical validity of family history of hereditary prostate cancer is relatively
strong when compared to other common hereditary cancers, such as breast and colon.
Most of the subjects in the selected studies recalled and document their family history of
prostate cancer with high levels of accuracy. The clinical validity of family history as an
instrument to stratify risk and predict future disease in an individual is not as well
supported. Likewise, the evidence supporting the clinical utility of family history in
improving health outcomes for men with prostate cancer is weak. There were no ethical,
legal, or social issues specific to family history and prostate cancer. But the ethical,
legal, and social issues are related to the potential for breach of privacy and
discrimination inherent to the nature of family health history and genetic information.
Additional quantitative and qualitative research is needed to evaluate the benefit and risk
of family history as a public health intervention method for addressing the health
disparity of prostate cancer in African-Americans.

Key Words
Family history, prostate cancer, African-American, hereditary, ACCE model,
analytical validity, clinical validity, and clinical utility.
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Introduction
Prostate cancer (PrCa) is the second most common cause of cancer death in men
(Center et al., 2012). The greatest risk for PrCa is found in older men, African-American
(AfAm) men, and men with a family history of PrCa. It is not clear why AfAm are at an
increased risk of developing and dying from PrCa. It is suspected that part of this
disparity is due to delayed diagnosis and limits in access to healthcare. Some studies
have suggested a genetic predisposition contributes to the increased prevalence and
mortality of PrCa in AfAm (Center et al., 2012).
The risk of PrCa increases dramatically in AfAms with a family history of PrCa.
AfAm men with a father or brother with PrCa have a one in three chance of developing
the malignancy. The risk increases to 83% with two affected first-degree relatives and
increases to 97% if they have three first-degree relatives with PrCa. It is not clear what
role hereditary PrCa plays in the increased incidence and mortality among AfAms
(Center, et al., 2012).
This systematic review of published literature used the ACCE model as
recommended by Yoon, Scheuner, & Khoury (2003) to improve understanding related to
factors that contribute to validity and utility of family cancer history data for hereditary
PrCa. The overall aim of this search strategy was to facilitate the examination of all
relevant published studies to identify family cancer assessment methods used in
American populations. Knowledge from such studies will be used to provide evidence
for the development of a valid family cancer history assessment tool and pedigree

17

analysis protocol for use in public health and preventive medicine to identify AfAm men
with hereditary PrCa.

Model
According to Yoon, Scheuner, & Khoury (2003), family history can be used as a
tool to stratify risk for common chronic diseases and thereby identify individuals with
increased risk of disease susceptibility. Yoon recommends a model developed by the
Center for Disease Control and Prevention’s Office of Public Health Genomics (OPHG)
(Centers for Disease Control and Prevention, 2010).

The model refers to the four

domains of the evaluation process: analytic validity, clinical validity, clinical utility and
associated ethical, legal, and social issues that influence both validity and utility (ACCE).
Initially the model was used to evaluate the validity and reliability of genetic tests. Yoon
suggest it is also may be used to evaluate the validity and utility of using family history
as a tool for predicting risk of hereditary disease. There are no existing studies that use
the ACCE model to examine the effectiveness of family history and disease.
The ACCE model is composed of a standard set of 44 questions and builds on
previously published methodologies and terminology introduced by the Secretary’s
Advisory Committee on Genetic Testing (Gudgeon, McClain, Palomaki & Williams,
2007). When implemented in its entirety, the ACCE model can require a year or more to
complete. Yoon et al. (2003) proposed a specific set of questions adapted from the
original 44 questions for the assessment of the validity and utility of family history
information for disease prevention. See Table 2.1 for the list of questions used to assess
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Table 2.1. Questions for Assessing Literature using ACCE Domains.

1.
2.

3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

17.
18.
19.
20.
21.

Analytic Validity Questions
What is the sensitivity and specificity for reporting each disease included in the tool?
How does the sensitivity and specificity vary by:
a. Type of relative
b. Proband characteristics
c. Disease Characteristics
d. Disease terminology
e. Phrasing of the question
How accurate is age of onset information?
What settings yield more valid information?
What formats yield more valid information?
What gold standards exist to validate the reported data?
Clinical Validity Questions
What is the natural history of the disease (may determine when family history should
be ascertained)?
Are there effective interventions for primary and/or secondary prevention?
Is there general access to the interventions?
What strategies could be adopted to improve compliance with recommended
interventions?
Are educational materials available to explain familial risk and the recommended
interventions?
What is the short-term and long-term impact of positive or negative family history or
screening and disease prevention?
Are there any health risks associated with the family history assessment and
subsequent interventions?
What are the financial costs associated with the family history assessment?
What are the economic benefits associated with interventions resulting from the
assessment?
What methods exist for evaluating and monitoring the family history assessment
process and its benefits and risks?
Clinical Utility Questions
What is the natural history of the disease (may determine when family history should
be ascertained)?
Are there effective interventions for primary and/or secondary prevention?
Is there general access to the interventions?
What strategies could be adopted to improve compliance with recommended
interventions?
Are educational materials available to explain familial risk and the recommended
interventions?
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Table 2.1. Questions for Assessing Literature using ACCE Domains. (continued)

22. What is the short-term and long-term impact of positive or negative family history or
screening and disease prevention?
23. Are there any health risks associated with the family history assessment and
subsequent interventions?
24. What are the financial costs associated with the family history assessment?
25. What are the economic benefits associated with interventions resulting from the
assessment?
26. What methods exist for evaluating and monitoring the family history assessment
process and its benefits and risks?
ELSI Questions
27. Are there legal issues regarding informed consent, ownership of the data, obligation
to disclose, or reporting requirements?
28. What is known about stigmatization, discrimination, privacy/confidentiality, and
personal/family and social issues associated with family history assessment and risk
labeling?
29. What safeguards have been described to protect privacy and are these safeguard in
place and effective?
Table adapted from Yoon, P. W., Scheuner, M. T., Peterson-Oehlke, K. L., Gwinn, M.,
Faucett, A., Khoury, M. J. (2002). Can family history be used as a tool for public health
and preventive medicine? Genetics in Medicine, 4, 304-310.

the literature in this review process. This literature review uses these 29 questions to
examine the literature related to family history and PrCa.

Disorder, Setting and Test
The presence of hereditary PrCa was first identified using diagrammatic family
history. This enabled the development of a description of a variant of PrCa distinguished
by early onset and autosomal dominant inheritance (Carter, Beaty, Steinberg, Childs, &
Walsh, 1992). Nearly two decades later, researchers still only identify hereditary PrCa
cases using family cancer history. Though there are several PrCa susceptibility gene
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variants, there is no clinically useful genetic test for hereditary PrCa. Hereditary PrCa is
correlated with a positive family history of PrCa including early age of onset, multiple
affected relatives, and a pedigree with an obvious Mendelian pattern of inheritance
(Carter, et al., 1992). Familial PrCa correlates with a positive family cancer with a
pedigree of at least two affected relatives but no indication of a Mendelian pattern of
inheritance (Carter, et al., 1992). In a sample of 95.5% European American (EuAm)
men, a group of researchers (Carter, Bova, Beaty, Steinberg, Childs, Isaacs, & Walsh,
1993) found that hereditary PrCa represented 5-9% of the total PrCa cases. Familial
PrCa represented 10-20%, with sporadic PrCa making up the majority at 74% of all PrCa
cases in the sample. These percentages are based on a EuAm majority sample, and
continue to be referenced and published as the prevalence of hereditary PrCa, familial
PrCa and sporadic PrCa within the US general population.
The health disparity of PrCa between AfAm and EuAm men is well documented
(Albain K.S., Unger, J. M., Crowley J. J., Coltman, C. A., & Hershman, D. L. 2009;
Jemal et al., 2008, Major, Oliver, Doubeni, Taskler, Keating, & Cutler, 2012). However,
the impact of hereditary PrCa on the incidence and mortality disparity of PrCa in AfAm
men is relatively unknown and needs further study.

A recent Cancer Disparity

Factsheet, published by the National Cancer Institute (NCI) of the National Institute of
Health (NIH), states that nearly all of the genetic variants associated with an increased
risk of developing PrCa are found most often in AfAm men. Certain combinations of
these polymorphisms are associated with a five-fold increased risk of PrCa in AfAm men
(National Cancer Institute, 2008). Given the correlation of hereditary PrCa with higher
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incidence of PrCa, migration toward younger ages, and more aggressive disease at earlier
ages this review focuses on evaluating the use of a family history survey as a public
health intervention to identify hereditary PrCa, assisting in the ultimate goal of
decreasing mortality in AfAm men.
Public health nurses monitor health trends and identify health risk factors unique
to specific communities. They set local priorities for health-related interventions to
provide the greatest benefit to the most people.

Public health nurses design and

implement health education campaigns and disease prevention activities, market locally
available health care programs and services to improve knowledge about access to care.
They also educate and provide direct health care services to vulnerable and at-risk
populations (American Nurses Association, 2007).
As baccalaureate nurse educators begin to incorporate the Essentials of Genetic
and Genomic Nursing Competencies, Curricula Guidelines, and Outcome Indicators
(Consensus Panel on Genetic/Genomic Nursing Competencies, 2009) into their
respective curricula, new graduates will be better prepared than their predecessors to
acquire multi-generational family history data and develop pedigrees from the data.
Advance practice nurses will also be prepared to analyze family history data and
pedigrees and estimate risks for Mendelian and multifactorial disorders as Essential
Genetic and Genomic Competencies for Nurses with Graduate Degrees was made
available to practitioners in 2012 (Greco, Tinely, & Seibert, 2012).
Without a genetic test for even one highly penetrant gene variant for hereditary
PrCa, family history remains one of the most commonly used methods for identifying
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individuals and families with possible causative variants of hereditary PrCa (Colloca &
Venturino, 2011).

Family history of cancer incidence information is collected in

genetic/genomic research and is used to infer risk of disease in population-based, casecontrol, cohort and family-based studies; yet little information is available on the
accuracy of reported family cancer history of AfAms. Most studies that have examined
the validity of family cancer history have included primarily EuAm samples, therefore
limiting the generalizability of their findings to AfAm men (Cerhan, et al., 1999; Keetch,
Humphrey, Smith, Stahl, & Catalona, 1996; Lesko, Rosenberg, & Shapiro, 1996; Spitz,
Currier, Fueger, Babaian, & Newell, 1991; Steinberg, Carter, Beaty, Childs, & Walsh,
1990).

Family Health History and Pedigree Analysis in Clinical Practice
Healthcare providers use family health history information to determine if there is
an increased risk of illness based on incidence in the family history.

Once risk is

determined, family history information is also considered when making clinical decisions
about treatment of disease. Family health history data is typically obtained by response
to a questionnaire. The questionnaire can be formulated as an electronic, interactive or a
written document. The information from the family health history questionnaire can be
transcribed into a pedigree for a more rapid and easier interpretation.
A pedigree is a standardized diagrammatic representation of family relationships
in which patterns of disease transmission are tracked.

The diagram facilitates

identification of patterns of inheritance and potentially shared environmental risk factors.
The pedigree should review at least three generations (Brock, Allen, Kieser, and
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Langlois, 2010) and contain information for the individual and relatives such as, relevant
health information, illnesses and age at diagnosis, ethnic background, age at and cause of
death, information of half siblings and consanguinity (Bennett, et al., 1995 & Brock, et
al., 2010). In addition the pedigree should be an evolving part of the medical record,
updated routinely along with medications, health history, and surgical history (Brock et
al., 2010).

Family History and Pedigree Analysis in Clinical Research
Family cancer history data is a critical variable in pedigree research.

The

pedigree developed from the family cancer history data is used to identify people with
increased risk for genetic disorders or with susceptibility to disease. Pedigree research is
often the precursor to genome-wide association studies and linkage analysis studies used
to discover genotypes associated with a disease or intermediate phenotype. Importantly,
pedigree research relies on accurate ascertainment of family history. One should suspect
hereditary cancer if the pedigree reveals multiple first-degree (FDR) and/or seconddegree (SDR) relatives affected with the same cancer, early age of onset, and
recognizable Mendelian inheritance pattern (Bastacky, Wojno, Walsh, Carmichael, &
Epstein, 1995; Carter et al., 1992; Carter et al., 1993; Spitz et al., 1991).

Family History and PrCa
There are three different epidemiological forms of PrCa: sporadic, familial, and
hereditary (Carter et al, 1992). Studies have concluded that there are no pathological
differences among these three epidemiological forms of PrCa (Bastacky et al., 1995;
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Kang, Maygarden, Mohler, & Pruthi, 2004; Keetch, et al., 1996). Currently there is no
clinical testing for genes involved in hereditary PrCa. In the sentinel study described
below, Carter and colleagues at Johns Hopkins University provided the first definition for
hereditary prostate cancer, referred to as the Hopkins Criteria, and 20 years later is still
the only method to identify hereditary PrCa.
In 1992, Carter used family history to define hereditary PrCa. An individual was
considered as having hereditary PrCa, if his family pedigree revealed a history of PrCa in
the following areas:

1. Three or more first-degree relatives (father, brother, son);
2. Three successive generations of either the maternal or paternal lineages; or
3. At least two relatives affected at or before the age of 55 years.

Men with familial PrCa also had a positive family history, but it was weakly positive and
insufficient to satisfy the hereditary PrCa criteria. Patients with no known family history
were considered to have sporadically induced PrCa (Carter et al., 1992). In a study of the
clinical impact of different definitions of hereditary PrCa, Sacco et al. (2005) simplified
the definition by stating “Sporadic PrCa is cancer occurring randomly in the population,
familial PrCa is unpredictable clustering of PrCa in families and, hereditary PrCa is a
strong clustering with early onset of PrCa in families” (pp. 762).
Carter et al. (1992) concluded that 43% of early age onset PrCa (disease onset
<55 years) was due to autosomal dominant inheritance of a rare allele. More importantly,
the group of researchers noted that early age onset hereditary PrCa constituted only a
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small proportion (9% by age 85) of all PrCa occurrences. This study results indicated
that only 2% of PrCa in EuAm men occurs in those aged less than 55. The same authors
concluded that the impact of hereditary PrCa in this population is the greatest in the
younger ages, less than 55 years of age (Carter et al., 1993).

Methods
Identification of Research Literature
Literature searches regarding utilization of family history and pedigree analysis as
a risk assessment tool for PrCa were conducted using PubMed and Cumulative Index to
Nursing and Allied Health Literature (CINAHL). A comprehensive literature search was
conducted for literature published between 2002 and 2012 using the search term(s) family
history, AfAm, and hereditary PrCa. The PubMed, Search Details feature, was reviewed
for accurate query translation of search terms and identification of Mesh terms. For a
summation of numbers of articles identified for review, see Table 2.2. Additional articles
(15/18 83%) were ascertained by manually searching through references cited in
publications.

Selection of Studies
The following criteria were used to guide selection of articles for review.
Inclusion criteria:
1.

Published in the English language.

2.

Utilized assessment of family history for PrCa.
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Table 2.2. Selection of Studies.

Database
Search Terms
PubMed
Hereditary Prostate Cancer
(1/1/2002-1/1/2012) Hereditary Prostate Cancer + Family History
Hereditary Prostate Cancer + Family History +
African-American
CINAHL
Hereditary Prostate Cancer
(1/1/2002-1/1/2012) Hereditary Prostate Cancer + Family History
Hereditary Prostate Cancer + Family History +
African-American

No. of Articles
Returned
55
31
5

5
1
1

Literature searches using PubMed and CINAHL was conducted for literature published
between 2002 and 2012 using the search term(s) family history, AfAm, and hereditary
PrCa.
3.

Research originated from an American institution of higher learning or health
agency.

4.

Address one of the four domains of the ACCE model.

Exclusion criteria:
1.

Primary focus was linkage or association of specific gene(s) or
polymorphism(s)

2.

Research originated outside of the US.

3.

Focused on secondary prevention, such as, family history and reoccurrence
after radiation therapy.

4.

Examined family history of cancer sites other than PrCa.

Thirty-three (35%) of the 94 studies found in PubMed originated outside of the
United States. Four studies focused on secondary prevention methods and two examined
family history reports of other cancers in men with PrCa. The seven studies from the
CINAHL were also reported in PubMed. After applying the exclusion criteria 55 articles
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remained. The abstracts for these 55 articles were reviewed for relevance to the ACCE
Model domains. Eighteen articles addressed at least one of the four ACCE domains.
Seven (38%) of the eighteen articles reported on cohort studies. The remaining articles
consist of two case control studies, one review article, one segregation analysis study,
three articles discussed ethical, legal or social implications and three articles address
clinical utility. See Table 2.3 for a list of the literature by ACCE domain.

Study Quality Assessment
To evaluate the quality of the cohort studies and the case control studies the
Critical Appraisal Skills Program (CASP) was used because of its specificity for case and
cohort studies (Public Health Resource Unit, 2006).

The CASP case-control study

appraisal tool consists of eleven questions designed to assist the reviewer to assess study
validity, results and relevance systematically (Public Health Resource Unit, 2006).
Similarly, the CASP cohort study appraisal tool consists of twelve questions designed to
assist the reviewer to systematically assess study validity, results and relevance (CASP,
2004). The CASP tool is designed so that the reviewer can answer yes, can’t tell or no to
each of the questions. To facilitate the quantitative evaluation of each study the reviewer
assigned a score for each response 2 = yes, 1 = can’t tell and 0 = no. The seven cohort
studies were given an average score of 20.4. The two case control studies received scores
of 18 out of possible 22 points. Most of the points were lost when asked if the study
results could be applied to the local population. Only two of the studies included AfAms
in the sample.
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Table 2.3. Literature Review Articles by ACCE Domain.
ACCE Model Domain

Review Articles by Domain

Analytical Validity

Carter et al., 1992
Kerber & Slattery, 1997
King et al., 2002
Ziogas & Anton-Culver, 2003
Weinrich et al., 2002

Clinical Validity

Makinen et al., 2002
Ziogas & Anton-Culver, 2003

Clinical Utility

Cotter et al., 2002
Carter et al, 1992
Drake et al., 2008
Beebe-Dimmer et al., 2006
Madersbacher et al., 2010

Ethical, Legal, & Social Issues

Yoon et al., 2003
Steck & Eggert, 2011
Bratt et al., 2006
Bloom et al., 2008
Giovannuci et al., 2007
Spain et al., 2008
Weinrich et al., 2007
Bonham et al., 2005

Selected articles for review. Inclusion criteria include: (1) English language, (2) use of
an assessment of family history for PrCa and (3) research originates from an American
institution of higher learning or health agency.

Results
Analytic Validity
In this review, analytic validity refers to how accurately family history tools
measure for hereditary PrCa among the respondent’s relatives. Analytic validity can be
separated into measures of sensitivity and specificity. Analytic sensitivity is a measure of
how well the family history tool identifies relatives who have been diagnosed with the
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disease of interest; in this review, it designates hereditary PrCa (Carter et al., 1992).
Analytic specificity is a measure of how well the family history tool identifies relatives
who do not have hereditary PrCa. Three studies examined the accuracy of a family
cancer history assessment related to PrCa.
The earliest of the three studies evaluated the sensitivity of subjects’ self-reported
family history for seven cancers recorded as a part of the Diet, Activity, and
Reproduction in Colon Cancer (DARCC) Study in the Utah Population Database (UPDB)
(Kerber & Slattery, 1997). Subjects were asked to enumerate their first-degree relatives
(parents, siblings, and children) by name and to identify the current age of each as well as
the family members who were dead and their age at death. Subjects were asked if each
relative had ever been given a diagnosis of cancer, and if a cancer diagnosis was reported,
to identify the type of cancer from a list. The Utah Cancer Registry, a population-based
cancer registry, was used to determine cancer incidence for the subjects’ relatives. The
linked UPDB-Utah Cancer Registry data were not complete and therefore did not serve
as a perfect “gold standard” to compare the DARCC interview data, but any cancer
recorded by the Utah Cancer Registry data for a family member identified through the
UPDB was regarded as confirmed.

The ability to confirm reports allowed for the

calculation of sensitivity of the subjects’ reports (Kerber & Slattery, 1997).
Kerber & Slattery (1997) found that sensitivities for breast (83%), colorectal
(73%), and prostate (70%) were all high and varied little between cases and controls.
The overall agreement (k; k=1 is total agreement) behaved in similar fashion. Agreement
was highest overall for breast cancer (k=0.61) and PrCa (k=0.61), colorectal (k=0.56)
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cancers were also viewed as being reported accurately. The DARCC subjects were found
to report family histories of cancer with 70-90 percent sensitivity and with little
suggestion of recall bias.

However, there was considerable variability among the

reported sites of the familial cancer in question. It was also noted that there was a high
degree of accuracy for reports of prostate, breast and colorectal cancers (Kerber &
Slattery, 1997).
King, Tong, Pack, Spencer, & Amos (2002) evaluated the feasibility of family
cancer history documentation in a sample of male patients (n=442) with PrCa seen in the
Prostate Clinic at the University of Texas M. D. Anderson Cancer Center.
Documentation was defined as “the percentage of records for which credible records
were obtained” (King et al., 2002 p. 547). Accuracy was defined as, “the percentage of
documented cancers that agree with the proband’s report” (King et al. 2002 p. 547).
Documentation and accuracy rates were provided for eighteen different cancers reported
by PrCa probands. Several cancers were reported with 100% accuracy including bladder,
brain, esophageal, kidney, lymphoma, melanoma, and pancreas.

Breast cancer was

reported with 95% accuracy and PrCa was reported with 86.2% accuracy (King, et al.,
2002).
Though the King et al. (2002) study did not report the sensitivity and specificity
of their family history tool, these measures were calculated based on the data provided in
the article. There were a total of 42 cases of PrCa reported. Of these cases, 25 were
confirmed. Thirteen cases of reported PrCa were not confirmed. By extrapolating the
missing data the sensitivity was calculated as 96.15% with a specificity of 43.33%.
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Based on self-reported family cancer history, the researchers were able to document or
confirm 96.15% of the PrCa cases. Conversely, the authors were unable to document or
confirm 57% of the self-reported PrCa cases (King et al, 2002).
Ziogas & Anton-Culver (2003) systematically evaluated the consistency of
proband-reported information on cancer in their first-, second-, and third degree relatives.
The objective of the study was to determine the probability of agreement between the
proband-reported statuses of cancer in a relative with the reference standard for various
cancer sites. This study was conducted at the University of California at Irvine, during
the creation of the proband family registries for breast, ovarian and colorectal cancers.
Malignancies reported for the relatives of the proband were verified by obtaining one of
several types of records—(a) pathology reports, tumor tissue samples, or clinical records;
(b) “self-reports” from affected and non-affected relatives of probands through structured
questionnaire and personal interviews; or (c) death certificates on deceased relatives.
This study found that the probability of agreement (PAC) for PrCa was 79.3 (70.0-88.6)
and the probability of agreement for no cancer (PANC) 98.8 (98.4-99.5) in first-degree
relatives. For second-degree relatives, the PAC for PrCa was 66.7 (55.1-78.2) and the
PANC was 98.1 (97.2-99).
Weinrich, Faison-Smith, Hudson-Priest, Royal, & Powell (2002) queried subjects
of the AfAm Hereditary PrCa Study to examine the stability of self-reported family
history of PrCa among AfAm men. Weinrich et al. (2002) reported the reliability of selfreported family history of PrCa in men asked about family history of PrCa on two
separate occasions; at the beginning and end of a one-year period. Their study found that
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one year after providing initial responses to family history of PrCa questions, 48% of the
AfAm men provided different answers (Weinrich et al., 2002).
The most important implications for research and practice gathered from the
literature are family history data should be validated using a “gold standard” to ensure
clinical decision making and research analysis is based on the most accurate data (Kerber
& Slattery, 1997; King et al., 2002; Weinrich et al., 2002; Ziogas & Anton Culver, 2003).
These ‘gold standards’ for verification of self-reported family health history can include
medical records, personal reports, and death certificates. Family history data researchers
and clinicians should note that family cancer history of first-degree relatives is
consistently found to be more accurate than that of second- and third-degree relatives
(Weinrich et al., 2002; Ziogas & Anton Culver, 2003).

Clinical Validity
Clinical validity (CV) refers to how well family history of disease can be used to
stratify disease risk and predict future disease in an individual. Similar to analytical
validity, CV is measured in terms of sensitivity and specificity. Clinical sensitivity is
estimated by the family history of a particular disease among a population based-group of
people with that disease. Clinical specificity is estimated by examining family history for
a particular disease among a population-based group of people without the disease.
In addition to sensitivity and specificity, the positive and negative predictive
values are also considered. In this review, positive predictive value is defined as the
probability that a person will have hereditary PrCa given their family history meets the
predetermined criteria.

Likewise, negative predictive value is the probability that a
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person will not develop hereditary PrCa, if their family history does not meet the
predetermined criteria. Two studies reported the clinical validity of family history related
to PrCa.
No American studies thoroughly examined clinical validity of family history in
relation to PrCa. Therefore, the following Finnish study was included in the review to
illustrate how clinical validity could be assessed in future American studies. In the first
round of the Finnish PrCa screening trial, Makinen et al. (2002) assessed the importance
of family history at the population level, in terms of program sensitivity and specificity.
Information on family history was obtained by use of a questionnaire at the time of
invitation. If the subject reported one or more first-degree relatives diagnosed with PrCa,
the family history was regarded as positive. Of the sample (N=20,311) providing family
history information through the self-administered questionnaire, 964 (4.7%) reported a
positive family history (one or more affected first-degree relatives). In the screened
population, 502 cancers were detected with only 29 cases reported by men with a positive
PrCa family history.

The program sensitivity for a positive family history as a

supplemental screening test was 5.9% (95% CI, 4.0% to 8.4%; 29 of 491). Importantly,
restriction of screening to the 29 men with a positive family history would have missed
94.1% of all PrCas detectable by screening. However, the specificity for family history
was 99.6%, limiting screening to men with positive family history would have correctly
identified 99.6% of men without the cancer. Inconsistent with other studies, this study
found that family history was not a good prognostic indicator for early detection of PrCa
among Finnish men with a family history (Makinen et al., 2002). Makinen et al. (2002)
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did address hereditary factors and found that the corresponding population-attributable
risk was 1.2%. They went on to conclude that identification of family with strong
hereditary component demonstrates the existence of genetic factors, but provides little
information regarding their importance at the population level.
Ziogas & Anton-Culver (2002) examined the validity of reporting family history
of cancer by probands in population-based and clinic-based family registries of breast,
ovarian, and colorectal cancers. In addition to calculating the sensitivity and specificity,
the positive and negative predictive values were calculated on the cancer status of
relatives by using a reference standard as described under analytic validity. The positive
predictive value in first-degree relatives for PrCa was 86.7% range: 74.7-94.5 and the
negative predictive value was 97.9 range: 96.3-99.7. The positive predictive value was
lower for second- and third-degree relatives (Ziogas & Anton-Culver, 2002).

Clinical Utility
Clinical utility refers to the assessment of the impact and usefulness of the family
history tool for individuals, families and society. Clinical utility addresses questions such
as if the family history information can be used to motivate a behavior change, can
classification of individuals into risk groups improve the effectiveness of available early
detection methods and interventions, are individuals more motivated to improve their
health if they know they may be at a higher risk than the average population, and will
individuals in the average-risk groups become complacent and therefore less likely to
engage in healthy behaviors (Yoon et al, 2002).
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Research literature suggests the presence of two epidemiologically distinct
classifications of PrCa. One group is characterized by earlier age at diagnosis and maleto-male transmission and the other group has later age at diagnosis without the male-tomale transmission (Cotter, Gern, Ho, Chang, & Burk, 2002). The assessment of family
history along with multigenerational pedigree analysis increases the likelihood of
identification of multiple affected family members, early age onset, and identifications of
patterns of inheritance that together can be used to identify men at high risk for familial
or hereditary PrCa. The men in these families with inherited predisposition to PrCa are
candidates for initiation of PSA testing at least 5 years before the earliest age of diagnosis
indicated in the pedigree (Bratt, 2006). If the family history data indicates prostate
related death or possible metastatic disease the men may need to start PSA screening 10
years before the age at which metastatic disease appeared and no later than age 50 years
(Bratt 2006). The American Cancer Society recommends screening for men at high risk
of PrCa from age 40 years or earlier. To emphasize, assessment of the family history of
all men with PrCa affords the chance for unaffected male relatives to be informed of their
risk and seek relevant counseling including development of a plan of care. Based on
these recommendations, physicians are likely to encourage screening at age 40 for AfAm
men (Bratt, 2006).
Carter et al. (1992) found that 43% of hereditary PrCa was diagnosed before the
age of 55 years but made up only 9% of all PrCa occurrences. Compared to PSA testing
in the general male population, testing men at high risk defined by family history can
affect the cost-benefit ratio in a positive way. The discovered incidence of multiple
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affected family members decreases the number of men tested to locate one case of PrCa.
More importantly, the positive predictive value of PSA is higher in men with positive
family history leading to a smaller proportion of healthy men with false positive tests
(Bratt, 2002).
One study has found that awareness of family history is a motivator for improved
screening uptake in men with a positive family history of PrCa (Bloom, Stewart, OakleyGirvans, Banks, & Chang, 2006).

Drake, Lathan, Okechucwu, & Bennett (2008)

reviewed data from the National Health Interview Survey and found that among men
with a family history of PrCa, AfAm men were more likely than EuAm men to have had
a PSA test. Their study also revealed AfAm men were screened more than EuAm men,
but AfAm men with a family history did not receive more screening than AfAm men
without a family history.
Giovannucci, Liu, Platz, Stampfer, & Willet (2007) used data from the health
professionals’ follow-up study (n=51,529), consisting of US male health professionals,
ages 40-75 years. This study identified the association of family history of PrCa with
AfAm race tended to be stronger for both total and advanced PrCa in the pre- prostate
specific antigen (PSA) PSA era. Beebe-Dimmer et al. (2006) examined the association
between family history of PrCa and breast cancer among AfAm men with PrCa. They
concluded a well-documented family history of all cancers among first-degree relatives
may signal a need for more aggressive PrCa screening practices and the adoption of
screening at an earlier age. These researchers also emphasized the need to inform AfAm
men of the significance of positive family history of breast and/or PrCa as a significant
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PrCa risk factor, in addition to race. Sharing a positive family history could have a
substantial impact on the recommendations for surveillance, and disease prognosis.
Likewise, AfAms should be encouraged to share news of their personal prostate and
breast cancer diagnoses with relatives to allow their family members to make early
informed decisions about cancer screening (Beebe–Dimmer, Drake, Dunn, Bock, Montie,
& Cooney, 2006).
A study by Madersbacher et al. (2010) examined the influence of family history
on PrCa risk to determine the implications for clinical management. They reported that
five to ten percent of PrCa cases were caused by a dominant inherited susceptibility to the
disease. Autosomal recessive and X-linked modes of inheritance were also suggested.
The study also reported a prediction that inherited genes (hereditary and familial PrCa)
contribute 42% of the total risk of developing PrCa with unshared environmental factors
(sporadic PrCa) making up the remaining 58% (Madersbacher, et al., 2010). Given
recent controversy over the positive predictive value of prostate-specific antigen (PSA),
family cancer history is an underutilized predictive factor that can alter risk estimation for
developing PrCa. Through the use of basic patient questioning family history is a simple
factor to assess in routine clinical practice and should be regarded as an important
parameter to consider, next to PSA, for PrCa risk assessment (Madersbacher, et al.,
2010).

Ethical, Legal and Social Issues
The ideology of genetic inheritance of PrCa or genetic predisposition to PrCa has
implications for every person with a family history of the malignancy.
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Social and

scientific researchers are just beginning to examine the ethical, legal, social aspects of
genetic testing and genetic research, including family history and pedigree research. The
most prominent ethical issues related to family cancer history and pedigree research are
associated with the potential for stigmatization, discrimination, privacy/confidentiality,
and the social implications of risk labeling. While the US Congress passed the Genetic
Information Non-Discrimination Act (GINA) in 2008 to prevent these problems, these
ethical issues may need to be addressed when working with vulnerable populations, such
as AfAm men.
AfAms are concerned about how their health information may be used to
discriminate against them. As briefly noted previously, AfAm may not be aware that
GINA went into effect in 2009 (Steck & Eggert, 2011). This law makes it illegal for
health insurers or employers with more than 15 employees to discriminate against
individuals based on genetic information. Genetic information includes an individual or
family member’s genetic tests, the occurrence of disease in family members, or the
individual or family member’s participation in research that includes genetic testing,
counseling, or education (Steck & Eggert, 2011). Failure of researchers to consider and
properly address these ethical issues may cause anxiety, impaired self-image, depression,
and/or self-blame for participants providing the family history information.
Unfortunately there were no studies that examine these ethical issues relative to PrCa.
Finally, researchers must be aware of the risk of discrimination and segregation
associated with categorizing humans by “racial” and “ethnic” groups and press forward
toward research to minimize the health disparity gap for diseases like PrCa in AfAms.
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Though no sharp genetic boundaries can be drawn between human population groups,
there are variations in frequency of certain polymorphisms and haplotypes within and
among populations (Bonham, Warshauer-Baker, & Collins, 2005). Discovery of such
variations may help researchers and clinicians understand why AfAm men are
disproportionately burdened with PrCa.

Discussion
AfAm males have the highest overall incidence and mortality rate from cancer
among all ethnic groups. The mortality rate from PrCa is 2-5 times the level seen in other
ethnic groups (Giuliano, et al., 2000). Researchers and health care providers continue to
search for an explanation for this persistent disparity. The history of poor minority
participation in clinical research and even poorer participation in genetics research
hinders scientific discovery and further potentiates the burden of cancer for this
population (Patel et al., 2010).
The result of this literature review guided by the ACCE model as described by
Yoon et al. (2002) revealed that family cancer history data and pedigree analysis has been
used in genetic research and is an analytically valid instrument for identifying men with
hereditary PrCa and familial PrCa. Clinically, there are many barriers to the collection of
family health history data in AfAm populations such as lack of knowledge of family
history, unwillingness to share family history, and inability to document family history
due to limited literacy. These barriers will have to be removed to adequately assess the
clinical validity of family cancer history in the AfAm population. It is possible that these
cultural and societal barriers may decrease the clinical validity and clinical utility of
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family cancer history assessment in the clinical and community healthcare settings.
Therefore, there is a need for continued evaluation of the clinical validity and clinical
utility of family cancer history information and pedigree analysis in AfAm men affected
with PrCa. There is also a critical need for additional research on the ethical, legal and
social implications of the outcomes of family cancer history and pedigree research, such
as the impact of being labeled high-risk based on ethnicity.
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CHAPTER III
MANUSCRIPT II: PILOT TEST OF COMMUNITY-BASED FAMILY HISTORY
TOOL AND PEDIGREE ANALYSIS TO PREDICT HEREDITARY PROSTATE
CANCER

Abstract
Background
Family history as a risk factor for prostate cancer is well established; however, the
risk is primarily based on samples from European and EuAm populations. The family
history questionnaire is the most commonly used predictive instrument for hereditary
prostate cancer. Early identification of hereditary prostate cancer in African-American
men is critical in order to promptly treat the cancer and prevent possible metastasis and
death. Several publications report the use of a family history questionnaire but very few
provide data related to the effectiveness of the tool. The goal of this pilot study was to
measure the use of a family history tool and pedigree analysis in a community setting to
predict hereditary prostate cancer in African-American males.

Methods
The sample was identified through African-American churches in a rural southern
state. After consent, family history tool was used to collect family cancer history data
from N=49 African-American men. Pedigrees were diagrammed from the provided
history data. Exploratory analysis was performed to describe the sample relative to
family history data. Logistic regression was used to examine relationship between family
history variables and the outcome of personal history of prostate cancer.
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Results
Age was the only detectable predictor of personal history of prostate cancer with a
chi square (1, N=49) =6.755, p =.004. Twenty-two percent of the sample reported a
personal history of PrCa (n=11). The South Carolina Central Cancer Registry was able to
confirm 56% of reported personal history of prostate cancer.

Conclusions
The comprehensive family history questionnaire and pedigree analysis was
effective to identify hereditary prostate cancer.

Larger sample size and additional

research are needed to further evaluate other predictors of hereditary prostate cancer in
this vulnerable population.

Introduction
Studies and epidemiological reports continue to reveal disparities in prostate
cancer (PrCa) incidence and mortality between racial and ethnic groups.

African-

American (AfAm) men in South Carolina have a 55% higher incidence rate and a 35%
higher mortality rate due to PrCa compared to European-American (EuAm) men (South
Carolina Central Cancer Registry, 2008). AfAm men in South Carolina have the highest
age-adjusted death rate for PrCa in the nation (Drake et al., 2006).

The genetic

predisposition of PrCa is well established and possibly the strongest among all common
cancers (Lichenstein et al., 2000, Varghese, & Easton, 2010), but the role of
genetics/genomics in the disproportionate incidence and mortality of PrCa in AfAm is not
well established.

Inherited PrCa occurs at younger ages with a more aggressive
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phenotype (Xu et al., 2010). Bratt (2002) reported that men with a family history of PrCa
are diagnosed, on average, six to seven years earlier than those without a positive family
history. The association with a positive family history is most likely caused by genetic
mutations, linked with a higher risk of PrCa (Boyle, Severi, & Giles, 2003). In Bratt’s
study, it was noted that more than 40% of men diagnosed before age 55 may have a
heritable etiology (2002). Studies have determined that heredity plays a role in incidence
of PrCa but the role of genetics/genomics in the disproportionate incidence and mortality
of PrCa in AfAm is not well established (Ahaghotu et al., 2004; Bratt, 2006). Given the
higher incidence rates of PrCa, the migration of initial diagnosis at younger ages, and
more aggressive disease at earlier ages some AfAm men from South Carolina may be
affected with a hereditary form of the malignancy (Shibata & Whittemore, 1997;
Mordukhovich, et al.,2011; Neider, Taneja, Zeegers, & Ostrer, 2003; Rennert, ZeiglerJohnson, & Addya, 2011).
The study of the role of genetics/genomics in PrCa in AfAm populations is
hindered because this population is less likely than EuAm to have family cancer
information documented in medical records. In a study of race and gender disparities in
hereditary colorectal cancer AfAms were found to have less knowledge of their paternal
family history of cancer compared to EuAms (Kupfer, McCaffrey, & Kim, 2006). This
lack of family cancer history information may contribute to the health disparity of PrCa
incidence and mortality as AfAms may not provide health care providers with the
information needed to assess risk and guide healthcare decision-making.

The most

commonly used instruments to study hereditary PrCa is a family history assessment tool
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and pedigree construction with analysis but the validity and utility of any family history
tool administered to a Southeastern AfAm population in a community setting is yet to be
determined.

Hypothesis and Specific Aims
Prior to developing a study to examine the ability of the model to assess risk of
hereditary PrCa in AfAm populations, it must first be determined if the model can
identify AfAm families with hereditary PrCa. Therefore, the purpose of this pilot study
was to measure the feasibility to use the family history tool and the pedigree analysis
portion of the model in a small sample of AfAm men.
The specific aims for this study include the following:

1)

Identify families with hereditary PrCa.
a) Use the Hopkins Criteria of hereditary PrCa as defined by Carter et al.
(1992) and as utilized in genetic research of prostate cancer to identify
pedigrees with obvious Mendelian patters of transmission of PrCa.
b) Determine the proportion of self-reported personal PrCa history that can
be confirmed through the SCCCR that will serve as a method of
identifying PrCa cases.
c) Identify the number of at risk individuals for each identified hereditary
PrCa family

2)

Identify variables in the family cancer history tool that best predict
hereditary PrCa.
a) H0—There is no relationship between age and personal history of PrCa.
b) H0—There is no relationship between having a father with PrCa and a
personal history of PrCa.

49

c) H0—There is no relationship between having a father with any cancer
and a personal history of PrCa.
d) H0—There is no relationship between having a brother with PrCa and a
personal history of PrCa.
e) H0—There is no relationship between having a brother with any cancer
and a personal history of PrCa.
f) H0—There is no relationship between having a sister with breast cancer
and a personal history of PrCa.
g) H0—There is no relationship between having a mother with any cancer
is and a personal history of PrCa.
h) H0—There is no relationship between having multiple brothers with
cancer and a personal history of PrCa.
3)

Evaluate the validity and utility of the family cancer history tool and
pedigree analysis of hereditary PrCa as used in a subset of the southeastern
AfAm men. The family cancer risk assessment model as evaluated using
statistical analysis of family cancer history data and pedigree analysis will
find significant correlation between known family history variables (age,
brother with cancer, father with cancer, multiple affected first degree
relatives.)
a) H0—There is no relationship between known predictor variables of
hereditary PrCa and personal history of PrCa.
b) H0— There is no relationship between confounding variables (education,
health insurance, time spent outside during daytime hours) and a
personal history of PrCa.
Materials and Methods

The Investigational Review Board (IRB) of Clemson University provided
approval for, Discovering HIStory:

Using Family History to Discover the Genetic

Predisposition for Prostate Cancer in African American Men. Because the family history
tool was administered in a community setting the investigator needed a way to confirm
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personal history of PrCa so an application was also submitted to and accepted by the
South Carolina Central Cancer Registry (SCCR) to validate the participant’s report of
personal history of PrCa.

Participants that documented a personal history of PrCa

completed an Authorization for Release of Protected Health Information Form (see
Appendix F).
A non-experimental, descriptive, correlational design was used for this pilot
study.

The most commonly reported approaches to successful recruiting of AfAm

participants as research subjects include community outreach through the church,
barbershop, civic organizations, and physician referral (Mastalski, Coups, Ruth, Raysor,
& Giri, 2008; Royal et al., 2000). Multiple approaches were used to gain access to the
AfAm churches in two rural South Carolina counties with limited results. Two separate
letters were mailed to the ministers of two AfAm Baptist Associations requesting their
support of the PrCa research by allowing the investigator to provide an educational
presentation on the role of family history in health promotion and cancer prevention at
churches in their respective associations. Contact was also made with the moderators of
each association to schedule a day and time to talk with the ministers and church leaders.
Seven of eleven ministers contacted agreed to support the presentation to their respective
congregations (see Table 3.1 and Appendix C).
To increase awareness and introduce the importance of family history, a
presentation titled “Discovering HIStory” was developed. This thirty-minute PowerPoint
presentation included information on the role of family history in assessing individual
risk of cancer, provided resources for documenting family health history and discussed
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Table 3.1. Participating Churches.
History
Packets
Packet
Males in
Not
Incomplete
Attendance
Personal
PrCa
Returned (Data Not
(Packets Histories History of Report
or
Included In
Church Date Distributed) Collected PrCa
Confirmed Completed Analysis)
1
10/26/11
13
3
0
NA
10
0
2
4/1/12
25
7
1
14
4
3
4/15/12
15
1
0
NA
14
0
4
3/18/12
23
5
2
17
1
5
3/25/12
10
6
3
4
0
6
2/19/12
13
13
4
0
0
thru
2/24/12
7
2/5/12
22
12
0
NA
10
0
8
4/8/12
54
4
3
50
0
Total
175
51
13
119
5
Male attendance at each church workshop and the number of family history tools
distributed and returned.

lifestyle modifications including diet, exercise, and cancer screening. Attendees were
given American Cancer Society brochures on breast, prostate and colon cancer.
Attendees also received a copy of a brochure developed by the investigator using a
template from the Genetic Alliance web site, titled Does It Run in the Family? A Guide
to Family Health History (see Appendix I).

The full 30-minute presentation was

presented at three of the eight AfAm churches. Abbreviated presentations were provided
at the remaining five churches following requests to minimize disruption of Sunday
morning worship service. The educational session was not part of the proposed research
and did not require IRB approval (see Figure 3.1).
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Figure 3.1. Education Program and Family History Study Model.

Men and women attended the Discovering HIStory Education Program. The men that
were interested in participating in the study remained after the program and after consent
was provided completed a family history tool and demographic form. Family pedigrees
were later developed from the information provided on the family history tool.

Study Population
The desired study population was AfAm males’ ages 18-80 years that attended
AfAm Baptist and Methodist churches in two rural counties of South Carolina.

Data Collection
The study was presented at the end of the educational presentation. To minimize
coercion and provide confidentiality, interested participants were invited to meet with the
investigator in a designated private room after the presentation to document their family
cancer history for use in the study. Once in the private room, the men were given the
consent form describing the risk, benefits, and their rights as participants in the study.
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The form was read to those individuals that indicated a literacy problem. After reviewing
the consent form, questions were addressed and answered. Upon signing the consent
form, the participants were given the family cancer history tool, which they completed
and returned to the investigator for review. When needed, the investigator read the tool
to participants and documented their responses. If the participant documented a personal
history of PrCa, the phenotype of interest, the participant was asked to complete an
additional form giving the researcher permission to confirm PrCa diagnosis through the
South Carolina Central Cancer Registry. The family cancer history tool, demographic
form, and consent form were labeled with participant ID numbers. Each participant was
given an 8” x 11” envelope and asked to seal their information in the envelope. The
envelopes were collected by the investigator and remained in the procession of the
investigator after leaving the community site. Upon return to a secure location the
information was removed from the envelope and the consent forms and release forms
were secured in a locked file cabinet.

Family Cancer History Tool
The family cancer history tool was designed for self-administration. The tool
consisted of a series of tables designed to elicit information to construct a threegeneration pedigree.

Information on some first cousins (third-degree relatives) was

obtained but no information was gathered on great aunts/uncles or great grandparents.
For each relative, the table included a place to provide age or age at death, cause of death,
type of cancer(s) diagnosis, and age at cancer diagnosis. To elicit the size of the family, a
separate table was provided where relatives could be listed, and an area to explain the
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exact relationship to the participant.

Space was also provided to indicate if the

participant had children with more than one partner or if the individual had half siblings.
This tool, adapted from a family history questionnaire published as part of a study of
family history in hereditary breast and ovarian cancer, can be viewed in Appendix A
(Armel et al., 2009).
In the hereditary cancer clinics, family history tools are used to triage patients for
genetic counseling and genetic testing. Armel et al. (2009) noted that in Ontario, Canada,
approximately 60% of hereditary cancer clinics in Ontario, Canada, used family history
tools in spite of the absence of evidence-based data related to their effectiveness. Their
study assessed the efficacy of the family history tool in use by one hereditary breast and
ovarian cancer clinic, the results supported that a family history tool is an effective tool
for assessing genetic testing eligibility. Similar to this pilot study, Armel et al. (2009)
used pedigrees developed from family history data, but explored the effectiveness of the
family history tool by comparing the pedigrees created from the tool to pedigrees updated
during genetic counseling. Results from the findings supported the modification of the
family history tool (Armel et al., 2009). The published copy, used in this study is
provided as Appendix B.

Definitions of Variables
Personal history of PrCa was the outcome variable. The main exposure variable,
family history of cancers, was defined as self-reported history of any cancer with a
special query for prostate and breast cancer among first-degree relatives including
parents, siblings, and offspring. Age was a continuous variable and recorded as number
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of years. Other covariates included education, health insurance, and sun exposure. The
variables of occupation, height, weight, though assessed on the demographic, were not
included in the data analysis due to inconsistent provision of information by participants.
A final question on the demographic form asked if the participant would be willing to
provide a buccal specimen as part of future research studies. This question was included
to assess the percentage of AfAm men willing to provide a buccal specimen in future
research of PrCa.

Statistical Analysis
An exploratory analysis was done to examine the characteristics of the study
participants. This involved consideration of the frequency of the categorical variables
and descriptive statistics such as the mean, range, standard deviation, and skew of the
continuous variables.
A Chi square (χ2) test examined the association between incidence of PrCa and
other categorical variables. The likelihood ratio statistic was used because it is more
robust when a small sample size results in small-expected cell counts.

Logistic

regression was used to examine association between incidence of PrCa and continuous
variables, and to examine how certain combinations of two independent variables impact
PrCa incidence.

When examining the impact of two independent variables the

Likelihood ratio Chi-square (χ2) test was used to determine if there was any significant
variable in the model. Finally, the Likelihood ratio Chi-square (χ2) statistic was used to
determine which specific variables were related to the odds of having PrCa. No power
analysis was performed to project sample size prior to this pilot study. The level of
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significance was p= 0.05, as this was commonly used in similar studies. All analyses
were conducted using Statistical Package for the Social Science (SPSS®) version 17.0
(SPSS, Inc., Chicago, IL).

Results
The purpose of this study was to pilot the proposed family history tool in a
community setting as a possible intervention method to identify AfAm men with
hereditary PrCa. The study sample (N=49) reflected an average subject age of 57 years
(range 36-79 years; S.D. 11.983). The majority of the men had health insurance and a
primary healthcare provider (91.7%, 81.6%). None of the men reported achieving less
than a high school education, 27.5% completed high school, 37.3% attended college, and
35.2% completed college. Table 3.2 provided the demographics of this pilot study.
Twenty-two percent (22%) of the AfAm men sampled had a personal history of
PrCa (see Table 3.3). Eleven participants reported a personal history of PrCa. Eight of
the eleven (72%) reported no family history of PrCa. Three of the eleven (27%) reported
having brother(s) with PrCa. None of the eleven participants with a personal history of
PrCa reported having a father with PrCa.

The Likelihood ratio (LR) for having a

personal history of PrCa given he has a brother with PrCa was 2.89 (p = 0.089). The LR
of having a personal history of PrCa given you have multiple brothers with PrCa is 6.71
(p = 0.082). Age was the only variable found to be significantly related to the incidence
of PrCa Likelihood ratio chi-square (χ2) (1, N = 49) = 10.193, p =0.001 (See Tables 3.43.6). The mean age at diagnosis was 62 years (S.D. 7.54). Table 3.3 shows the reported
family history of cancer. The variables daytime hours spent outside, having health
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Table 3.2. Participant Demographics.
Characteristics
Males
Mean age (range)
Age at diagnosis (range)
Health Insurance
Education

Number
49
57 (36-79)
61 (53-79)
41 (3 missing)
14 Completed HS
18 Some College
17 Completed College

Percentage
100%

91.7%
27.5%
37.3%
35.2

Average age for pilot sample (N = 49). Age at diagnosis for participants that reported a
personal history of PrCa. Number and percentage of participants with health insurance.
Level of education as reported by each participant.

Table 3.3. Percentage of Sample Reporting Family History of Cancer.
Family History
Personal History of PrCa
Mother with cancer
Father with Cancer
Father with PrCa
Brother with Cancer (other than PrCa)
Brother with PrCa

Sister with Cancer (other than breast cancer)
Sister with Breast Cancer

Number
11
9
9
5
1 brother- 5
1 brother-1
2 brothers- 1
3 brothers - 1
1 sister -4
2 sisters- 1
1 sister- 4

Percentage
22%
18%
18%
10%
10%
2%
2%
2%
8%
2%
8%

Proportion of the participants (n=49) with a family history of cancer. For example, 4 of
the participants had 1 sister with cancer and 1 participant had 2 sisters with cancer.
Table 3.4. Chi-Square (χ2) and p-values for age (continuous) predictor variable.
Variable
Age

Likelihood Ratio ChiSquare (χ2)
10.193

df

N

p-val

1

49

.001

2

Note. p<0.05. Age was found to be significant, LR (χ ) (1, N = 49) = 10.193, p =0.001
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Table 3.5. Chi-Square (χ2) and p-values for each (categorical) predictor variable.
Variable
Education
Primary MD
Health Insurance
Inside/Outside
Mother_Ca
Father _Ca
Father _PrCa
MGM_Ca
MGF_Ca
PGM_Ca
PGF_Ca
Num Br_Ca
Br_PrCa
Num_Br_PrCa
Num_S_BrCa
Num_MA_Ca
Num_PA_Ca
Num_ PU_Ca
Num_MU_Ca

Likelihood Ratio
0.666
0.000
1.131
0.565
0.922
0.922
2.703
1.581
0.199
1.041
0.514
5.546
2.892
6.711
0.016
1.795
0.514
0.542
1.460

df
2
1
1
1
1
1
1
1
1
1
2
2
1
3
1
2
1
2
3

N
49
49
49
49
49
49
49
49
49
49
49
49
49
49
49
49
49
49
49

p-val
.717
.986
.288
.452
.337
.337
.100
.804
.655
.308
.473
.062
.089
.082
.900
.408
.473
.763
.692

Note: p<0.05. Direct logistic regression for each predictor variable of the family history
revealed a likelihood ratio. None of the predictors significantly predicted a personal
history of PrCa. Brothers with PrCa, having a brother with PrCa and Number of brothers
with any cancer approached significance.
Key—CA-cancer, MGM-maternal grandmother, MGF-maternal grandfather, PGMpaternal grandmother, PGF-paternal grandfather, Num- number, Br- Brothers, PrCaprostate cancer, BrCa-breast cancer, PU-paternal uncles, PA- paternal aunts, MUmaternal uncles, MA-maternal aunts, MD-medical doctor.
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Table 3.6. Regression analysis for select predictor variables.
Variables

Likelihood
Ratio (χ2)
Omnibus test
10.193

p-val

Likelihood
Ratio (χ2)

p-val

.001

Age

6.755

0.009

Age_Education

10.476

.015

Age
Education

9.810
0.283

0.002
0.868

Age_Num_S_Ca

12.908

.005

Age
Num_S_Ca

12.383
2.715

0.000
0.257

Age_ Num_Br_PrCa

14.436

.006

Age
Num_Br_PrCa

7.725
4.243

0.005
0.236

Age_Father_PrCa

13.589

.001

Age
Father_PrCa

10.886
3.396

0.001
0.065

Age_Inside/Outside

12.820

.002

Age
Inside/Outside

12.255
2.627

0.000
0.105

.000

1.00

Age
Age at Dx

0.000
0.000

0.993
0.993

10.342

.006

Age
Primary MD

10.342
0.150

0.001
0.699

Age

Age _Age at Dx

Age_Primary MD

Sub variable

Note: p< 0.05. The Likelihood Ratio statistic of the Omnibus test and the respective pvalue were used to determine whether two predictor variables when placed in the
regression model as main effects were significant. If the omnibus test was significant
then the Test of Model Effects was considered to see which of the two variables (sub
variables) contributed to the outcome = personal history of PrCa. In every model age was
the significant predictor variable.
Key: Ca—cancer, Dx—diagnosis, Num—number, MD— medical doctor.

insurance, level of education, having a mother with cancer, having a sister with cancer,
having a sister with breast cancer, having a brother with PrCa and having a father with
cancer, and having a father with PrCa were not found to be significant at an alpha of 0.05.
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Discussion
The following discussion is guided by the specific aims of the pilot study.
Specific aim one was to identify families with hereditary PrCa. The Hopkins Criteria of
hereditary PrCa as defined by Carter et al. (1992) was utilized to identify pedigrees with
obvious Mendelian patterns of transmission of PrCa. There was one participant who met
the criteria for hereditary PrCa; with three affected brothers and one affected paternal
uncle. Another participant was diagnosed with PrCa at the age of 53 years, but did not
report having any other family members affected with PrCa. Early onset, < 55 years of
age, is a criterion for hereditary PrCa; but, there must be at least two affected relatives
under the age of 55 years (Carter, et al., 1992).
An additional objective of specific aim one was to determine the proportion of
self-reported personal PrCa history that can be confirmed through the SCCCR that will
serve as a method of identifying PrCa cases. Thirteen participants reported a personal
history of prostate cancer. Only eleven of the participants’ family history and pedigree
information were included in the statistical analysis. As reported earlier, three of the
participants were brothers and though all three had a personal history of prostate cancer
only one brother’s family history data was included in the analysis. Seven participants
provided authorization for release of health information.

Four or the seven (57%)

personal histories were linked positively to the SCCCR database. The SCCCR database
contains prostate cancer history from 1996-2009. The family history tool asked for age
of diagnosis, whether the participant lived in South Carolina at the time of diagnosis, city
and county of diagnosis, did the diagnosing physician practice in South Carolina, and the
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name of the physician. But on the authorization form used by SCCCR to search the
database only the full name, date of birth, address, and phone number are provided.
Additional information from the demographic portion of the tool, such as name of
diagnosing physician, name of physician that treated prostate cancer, and if physician that
diagnosed the PrCa practice in South Carolina should be added to the authorization form
to aide with linkage. Space to document the year of diagnosis beside the age at diagnosis
will also facilitate linkage in the SCCCR database.
The final objective of specific aim one was to identify the number of at risk
individuals for each identified hereditary PrCa family. The only hereditary PrCa family
has a total of 26 males. The pedigree suggests that a variant genotype predisposing to
hereditary PrCa is possibly in the paternal lineage, therefore there are 13 possible male
carriers of the variant genotype. Five of the thirteen males are deceased, four have the
phenotype (PrCa) and are living, and four do not have the phenotype. At the time of the
assessment 30% of the males in this family are affected and 30% are at very high risk.
The relative risk of the participant’s unaffected brother for developing PrCa by the age of
70 is 35.23 (95% CI: 27.74, 44.62). The relative risk for the participant’s son and
nephews for developing PrCa by the age of 60, considering all of their fathers developed
PrCa by the age of 60 years, is 11.99 (95% CI: 9.4, 15.18) and by age of 70 years their
relative risk is 35.23 (95% CI: 27.74, 44.62) (Nieder, Taneja, & Zeegers, 2003).
Specific aim two was to identify variables in the family cancer history tool that
best predict hereditary PrCa. Known predictors of hereditary PrCa are three or more
first-degree relatives with PrCa, relatives with PrCa in three successive generations of
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either the maternal or paternal lineage or at least two relatives diagnosed with PrCa
before the age of 55 years. Age was the only statistically significant predictor of personal
history of PrCa. None of the individuals in the hereditary prostate cancer family were
diagnosed before the age of 55 years. There was only one participant that reported being
diagnosed with PrCa younger than 55 years, he was 53 years of age at diagnosis, but he
had no other family history of PrCa. Due to the small sample size and the selected
statistical analysis method it was not possible to reject the null hypothesis (b-h)
previously noted for specific aim two. It is worth noting that the predictor variables
brother with PrCa and number of brothers with PrCa approached statistical significance at
LR 2.89 (p = 0.089) and 6.71 (p = 0.082), respectively.
The third specific aim was to evaluate the validity and utility of the family cancer
history tool and pedigree analysis of hereditary PrCa as used in a pilot sample of the
southeastern AfAm men. Due to the small sample, only one hereditary PrCa family was
identified and the statistical analysis method of logistic regression instead of multinomial
regression, the study failed to reject the null hypothesis that there is no relationship
between known predictor variables of hereditary prostate cancer as defined by Carter et
al. (1992) (early age onset, multiple affected first-degree relatives i.e., brothers, sons, and
a father). The study was unable to reject the null hypothesis that there is no relationship
between the confounding variables and hereditary prostate cancer. Statistically rejecting
the null hypothesis would have favorably impacted the analytical validity of the piloted
risk assessment model.

63

Conclusion
This study showed that age, even in this small sample, is a strong predictor of
PrCa. It also found that the piloted family history tool and pedigree analysis method has
marginal analytical validity. According to the National Cancer Institute (2011), 5-10% of
the total cases of PrCa in the general population are hereditary PrCa. Therefore, it was
expected that out of 11 cases of PrCa there would be one case of hereditary PrCa. In this
study sample of 11 cases, one participant met the criteria for hereditary PrCa. One of the
most promising findings of this study is the similar age related incidence, regardless of
the small sample size (see Figures 3.2 and 3.3). The nearly parallel alignment of the age
related incidence potentially indicates that the selected rural southern population is
affected with PrCa in a manner that closely mimics that of the rest of the state and nation.
The process of designing this study has equipped this novice researcher with the
experience and knowledge to improve the study design, statistical analysis methods and
recruitment in future studies. The investigator plans to modify the family history tool and
continue to pilot it in a public health setting to evaluate and improve the analytical
validity.

Implications for Translational Research
The purpose of this study was to pilot the proposed family history tool in a
community setting as a possible intervention method to identify AfAm men with
hereditary PrCa. Using the four domains of the ACCE model as published by Yoon et al.
(2003), for evaluating family history as a predictive and risk assessment tool this study
starts to examine the element of analytic validity of a specific family history tool and
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SPSS table presents the number of participants (vertical axis) for each age (horizontal
axis). Count = number of participants. Green bars= participant reported a personal history
of PrCa. Blue bars = participant did not report a personal history of PrCa. Illustrates the
age at diagnosis for those with a personal history of PrCa tends to be in the lower half of
the table, which is consistent with prostate cancer being a disease that affects older men.
Figure 3.2. Personal History of PrCa.
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National (SEER), State (SCCCR), Discovering
History Comparison of Age at Diagnosis
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10
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20-34

35-44

45-54

55-64

65-74

75-84

>84

Age Groups

Comparison of the percentage of individuals diagnosed within each age group for the
Discovering HIStory pilot sample against that reported for national SEER data and the
state cancer registry. Though the sample size was relatively small for the study the data
is comparable to that of the national and state populations of AfAms.
Figure 3.3. National (SEER), State (SCCCR), Discovering History Comparison of Age
at Diagnosis.

pedigree analysis model. In this particular study analytic validity indicates how well the
family history tool and pedigree analysis identifies and measures hereditary PrCa.
Kerber & Slaterry (1997) & Zioags et al. (2003) found the proband’s report of cancer
among affected relatives demonstrates a high degree of accuracy for PrCa. Accurate
family history data lends to the validity of the family history tool as an assessment
instrument.

This study did not attempt to verify disease status of relatives of the

participant, but for the participant who reported a personal history of PrCa it was
concluded that 56% had verifiable cases of PrCa through the South Carolina Central
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Cancer Registry (SCCCR). More importantly the ability of the SCCCR to be able to link
to the limited data and confirm four of the seven cases is encouraging.

In future

investigation of the model, with a larger community based sample, the SCCCR will serve
as the “gold standard” for confirming cases of PrCa.
Validating the personal history of the participant was the first step in assessing the
analytical validity of a tool designed for use in a clinical setting. Had the research been
conducted in a clinical setting the investigator would have access to medical records as
method of confirming the participant’ health status. Future research is needed to evaluate
the remaining domains of the ACCE model, clinical validity, clinical utility, and ethical,
legal, and social implications.
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CHAPTER IV
MANUSCRIPT III: USE OF FAMILY HISTORY AND PEDIGREE IN PUBLIC
HEALTH NURSING TO IDENTIFY AFRICAN-AMERICAN MEN AT RISK FOR
HEREDITARY PROSTATE CANCER: CASE REPORT

Abstract
One goal of Health People 2020 is to” improve health and prevent harm through
valid and useful genomic tools in clinical and public health practices.” Prostate cancer is
a public health problem with a disproportionate impact in African-American populations.
Higher incidences of prostate cancer migration towards earlier ages, and more aggressive
disease at younger ages in African-American imply a genetic predisposition to the
malignancy. Implementation of initial screening and health promotion measures earlier
in the lives of African-American men, who are at exceedingly high risk due to ethnicity
and hereditary factors, needs to be established as a national guideline much like women
in families with hereditary breast cancer. Increasing scientific evidence supports the
health benefits of using family health history tools to guide clinical and public health
interventions. This case report demonstrates how a comprehensive family health history
questionnaire and the resulting pedigree can be used as a public health nursing
intervention to identify AfAm men at risk for hereditary prostate cancer. The manuscript
illustrates how knowledge of family history can be used to identify unaffected at-risk
males and serve as a stimulus for community based educational programs.

Such

programs can be designed to decrease the health disparity of prostate prostate cancer in
African-American communities by empowering men with the information to decrease
fear and anxiety while promoting health and preventing disease.
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Introduction
Prostate cancer is a major worldwide public health problem. As many as one in
six men in the US will be affected with prostate cancer (PrCa) (Howlander, et al., 2012).
Estimated worldwide incidence annually is 899,000 new cases per year with, 186,320 per
year in the US (Globocan, 2008).

Approximately 5-10% (44, 950 to 89,900 cases

worldwide and 9,316 to 18,632 cases in the US) of the total PrCa burden follows a
Mendelian inheritance pattern (Carter et al., 1993). Researchers continue to search for
causative germ-line mutations.

In the US, African-American (AfAm) men have an

estimated annual PrCa incidence of 250,000 cases (CDC, 2012). If the 5-10% proportion
of hereditary PrCa holds true for AfAm men, approximately 12,500 to 25,000 men are
affected with hereditary PrCa. The higher incidence of PrCa, the migrations toward
earlier ages, and more aggressive disease at younger ages in AfAm imply a genetic
predisposition to the malignancy.

Therefore, implementation of earlier screening

protocols of AfAm men, who are at exceedingly high risk as a result of ethnicity and
hereditary factors, are strongly recommended.

The challenge then becomes the

identification of AfAm men at risk for developing hereditary PrCa. This manuscript
proposes the use of a comprehensive family cancer history tool and pedigree analyses as
a cost efficient method for public health nurses to identify AfAm men at extremely high
risk for PrCa. A case report is used to demonstrate how data from a comprehensive
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family cancer history tool is translated into a multigenerational pedigree for easy
recognition of hereditary PrCa.
Following the suggestions of Yoon, Scheuner, & Khoury, (2003) a simple, easily
applied, and inexpensive public health-oriented, family history tool designed for use in
diverse populations was used for collection of information. Though simple, the tool
allowed for collection of enough information to make prediction possible; therefore,
facilitating the classification of individuals into different risk groups (Yoon, Scheuner, &
Khoury, 2003).

Case Report
In a pilot study of a family cancer history questionnaire, AfAm men (N=49)
provided family cancer history data transmitted into pedigrees and analyzed to determine
factors that best predict familial and hereditary PrCa. Of the 49 histories, only one family
met the criteria of hereditary PrCa. Three of five male siblings attended the Discovering
HIStory educational program and each completed a family history questionnaire. One of
the brothers had a family history questionnaire used in the study, but the respective
family cancer histories corroborated the history provided by the participating brother.
Characteristics of the pedigree are described below.

All medical history was self-

reported and permission to share information within the family unit was obtained prior to
disclosure.
In the case study, four brothers and a paternal uncle were affected with PrCa;
therefore, meeting the Hopkins Criteria (Carter, Beaty, Steinberg, Childs, & Walsh,
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1992); three or more affected first-degree relatives (father, brother, son). Figure 4.1
shows the pedigree as of May 2012.
The consultand, indicated on pedigree in position III.2, sought medical attention
for difficult urination. Consultand III.2 reported prostate-specific antigen (PSA) of 8
mg/dL (Reference range 0-4ng/dL) upon consultation with a primary care provider.
Prostate biopsy confirmed PrCa, which was initially treated in 2003 with cryosurgery.
Increasing PSA levels in 2009, prompted additional cryosurgery, with confirmation of
aggressive PrCa diagnosis. The consultand was not a candidate for prostatectomy due to
obesity and other comorbidities, so hormone ablation was performed in 2010.
Relative III.3, now 67 years of age, was diagnosed with PrCa at 55 years of age.
He presented to primary care provider with problems urinating: “I always felt like I had
to go, but even after I went I still felt like I had to go.” PSA at the time of diagnosis was
4.5 ng/dL. No additional details of his medical work-up were provided, but reported
treatment with successful results.
Relative III.8, the youngest of the brothers, was diagnosed with PrCa during a
routine annual examination. No symptoms were reported and PrCa was only detected
with an elevated PSA; the exact PSA level was unavailable with recall. Age at diagnosis
57 years and treatment was seed radiation. He continues to see his doctor regularly, and
reports his last “check-up” was “good.”
The three brothers all reported there is an older brother, relative III.1. who was
recently diagnosed with PrCa. Due to his advanced age (71 years), other health issues,
and the recommendation of his doctor, treatment for PrCa has not been initiated. One
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Figure 4.1. Hereditary Prostate Cancer Pedigree.

paternal uncle was also reported to be diagnosed with PrCa. It was also noted the father
of the brothers died at age 30 in an accident (See Figure 4.1).

Discussion
Public health nurses monitor health trends and identify health risk factors unique
to specific communities. They set local priorities for health-related interventions to
provide the greatest benefit to the most people, design and implement health education
campaigns and disease prevention activities, educate communities regarding locally
available health care programs and services to improve access to care, and educate and
provide direct health care services to vulnerable and at-risk populations (American
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Nurses Association, 2007). It is known that PrCa is a public health problem that has a
disproportionate impact in AfAm populations. In Healthy People 2020, a health disparity
is defined as:

A particular type of health difference that is closely linked with social,
economic, and/or environment disadvantage. Health disparities adversely
affect groups of people who have systematically experienced greater
obstacles to health based on but not limited to their racial or ethnic groups,
socioeconomic status; gender; age, cognitive ability, physical ability,
geographic location or other characteristics historically linked to
discrimination or exclusion. (US Department of Health and Human
Services, 2010, “The Future Genomics in Public Health”).

While not considered a genetic test, but used in surveillance of prostate cancer,
the US Preventive Service Task Force (USPSTF) recently rendered a recommendation
grade of “D” for PSA screening. The final recommendation grade of “D” indicates that
the USPSTF is against the use of PSA screening for PrCa (Moyer, 2012). Without a
diagnostic or predictive genetic test for PrCa and major debate over the benefit of PSA
screening, healthcare providers will need to rely more than ever on a complete family
health history.
There is some research on the validity and utility of family health history tools in
clinical settings of clinical research and primary care, but there is a marked deficit of
research in the validity and utility of family health history tools in public health settings
and as a public health intervention. In an effort to accomplish the goal to improve health
and prevent harm through valid and useful genomic tools in clinical and public health,
Health People 2020 proposes specific objectives involving family history and genetic
test. The specific objectives are included Table 4.1.
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Table 4.1. Healthy People 2020 Objectives Related to Family History and Genetic Test.
1.

Creating and evaluating scientific evidence to support valid and useful genetic test
and family health history tools;

2.

Developing evidence-based practice recommendations that evaluate the net health
benefit of genetic tests and family health history tools;

3.

Conducting research on how to translate recommendations into practice;

4.

Facilitating the use of valid and useful family health history tools to guide clinical
practice, policy, and national, State, and local programs to find people who are at
risk for disease, make diagnoses, and provide appropriate interventions;

5.

Monitoring the use of genetic tests and family health history in populations, the
health outcomes related to their use, and disparities in use and outcomes; and

6.

Improving health and prevent harm through valid and useful genomic tools in
clinical and public health practices (US Department of Health and Human
Services, 2012).

Table adapted from US Department of Health and Human Services (2012). Healthy
People.gov. Retrieved from http://www.healthypeople.gov/2020/default.aspx.

This case report stems from a pilot study of a family cancer history tool and
pedigree analysis used as a part of community health education program. The pilot study
was designed to address objectives three and four Healthy People 2020. Family cancer
history tools and pedigree analysis are used in genetic/genomic research to identify
hereditary PrCa families; the aforementioned pilot study examined the effectiveness of a
research method as a public health intervention. More importantly this pilot study was
the first step in validating a family cancer history tool for use in public health settings to
help AfAm men recognize their risk of PrCa and to assist public health nurses identifying
high risk individuals who may benefit from targeted health promotion and early screening
efforts.

76

Implications for Nursing Practice
All three of the brothers were managed medically for their respective PrCa, but
the implication for the public health nurse comes with the knowledge there are four males
(1 male in generation III and 3 males in generation IV) who may benefit from targeted,
early screening and health promotion.

The health promotion efforts should include

education targeting these at-risk males. The educational materials need to incorporate
information of risk factors for PrCa including genetics, race/ethnicity, family history, age,
diet, obesity, and chronic inflammation. To obtain the greatest impact the nurse should
encourage the at-risk males to share the materials and information with first and seconddegree young-adult male relatives. The following content summarizes the current body
of evidence related to the utilization of family history in the study of genetic and
environmental risk factors of PrCa.

The studies selected for this manuscript were

conducted in the US since the completion of the Human Genome Map in 2003 and
examined risk factors of PrCa.

Inherited Genetic Risk Factors
With the completion of the Human Genome Map in 2003 and continued advances
in technology linkage analysis and genome-wide association, research continues to
examine and evaluate the hypotheses generated by aggregation and segregation analysis
of prostate cancer. The following synopsis of literature summarizes some of the known
genetic risk factors of PrCa, a very complex, polygenic disease.
Xu et al. (2005) conducted a genome-wide linkage scan of families (N=1,233)
with PrCa. In the first analysis of all families, researchers found no significant evidence
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of linkage in the total genome. However, evidence of suggestive PrCa linkage was
observed at five chromosomal regions on the long arms (q) of the chromosomes 5, 8, 15,
17 and 22 at different loci (5q12, 8p21, 15q11, 17q21, and 22q12).
Families were further divided into subsets (n=269) to determine if genes were
more likely to segregate in families with stronger family PrCa risk; families with at least
five affected members or with family mean age at diagnosis of < 65 years. Those with a
stronger family PrCa risk demonstrated stronger evidence of linkage in the six regions.
Two (17q21 and 22q12) were noted in the original analyses and four in new regions.
Among this subset of families, at least five had affected members with linkage in six
regions, two, 17q21 and 22q12, previously identified in the primary analysis of the entire
set of families.
The secondary analysis of the subset of families with mean age at diagnosis of <
65 years (n=606) revealed evidence of linkage in four regions on both the short (p) and
long arms (q) of chromosomes 3, 5, 11 and X; specifically loci 3p24, 5q35, 11q22, and
Xq12. None of these regions were found in the previous two analyses. Currently, these
regions only suggest possible locale of major PrCa susceptibility genes (Xu et al., 2005).
Many chromosomes have been linked to hereditary PrCa, though none with a
specific causative variant.

One study identified multiple regions of suggestive

chromosomal linkage by stratifying EuAm families according to age at PrCa diagnosis
and number of affected men within each family.

Similar methods of genome-wide

scanning detected three distinct chromosomal loci at 11q25, 15q26, and 17p12. Even
families with a weak familial history of PrCa had loci detected at chromosome regions
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7q21, 8q22, 15q13-14, and 2q21. These were totally distinct from those located by Xu et
al. in their 2005 study (Stanford et al., 2009).
Using the linkage of one of the regions found in the Xu et al. (2005) study, Zheng
et al. (2005) conducted a fine mapping linkage analysis and evaluation of candidate gene
NKX3.1 located at 8p21. This gene was selected because of its known function and
location within a chromosomal region where evidence for PrCa linkage and somatic loss
of heterozygosity is found. NKX3.1 is a homeodomain-containing transcription factor
that is expressed in a largely prostate-specific and androgen-regulated manner (Zheng et
al., 2005).

The protein producing NKX3.1 gene exerts a growth-suppressive and

differentiating effect on prostate epithelial cells (Bowen, et al., 2000). To examine this
gene, the researchers re-sequenced the gene from159 probands with a diagnosis of cancer
who provided a hereditary PrCa family history, each family with at least three firstdegree relatives affected with PrCa. This study was the first report in which germ-line
variants of the NKX3.1 gene, a gene largely prostate-specific and commonly deleted in
prostate tumors, were systematically evaluated in a large number of hereditary PrCa
families. Both common and rare germ-line variants in the NKX3.1 gene were identified
and were linked to PrCa risk in 188 hereditary PrCa families (Zheng et al, 2005).
Researchers using a recent case-control study conducted an analysis of 13 PrCa
susceptibility chromosomal loci to study the genetic associations with family history and
clinical features. It was found that 11 single nucleotide polymorphisms (SNPs) were
significantly associated with PrCa risk in their EuAm population.

The strongest

association was found with 10q11 and 17q12 (OR= 1.21; 95% CI 1.17-1.47; OR= 0.77;
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95% CI 0.69-0.86 respectively), demonstrating that the PrCa cases were 1.21 times more
likely to have the 10q11 polymorphism than the study controls. Similarly PrCa cases
were 0.77 times more likely to have the 17q12 polymorphism than the study controls.
Like older studies that specifically examined aggregation of PrCa, this study found an OR
of 2.19 (95% CI 1.77-2.74; p < 0.0001) in EuAm men with a first-degree family history
of disease (Fitzgerald, 2009).
Gene alterations on chromosomes 1, 17, and the X-chromosome have been
extensively studied and are associated with a family history of PrCa. The hereditary
PrCa (HPC1) gene and the ‘predisposing for cancer of the prostate’ (PCAP) gene are on
chromosome 1, while the ‘human PrCa gene’ is on the X chromosome. In addition, much
like percentages seen with the breast and ovarian cancer syndrome, genetic studies
targeting PrCa suggest a strong familial predisposition may be responsible for as many as
5-10% of PrCa cases (Ford et al., 1998; Gronberg et al., 2003; Theodorescu et al., 2009).
The proposed patterns of inheritance for PrCa are autosomal dominant inheritance
and X-linked recessive inheritance (Carter, Beaty, Steinberg, Childs, & Walsh, 1992;
Monroe et al., 1995).

Inherited polymorphic variants of genes mediating androgen

action, AR (CYP17, and SRD5A2) also influence the development and progression of
PrCa (Nelson, De Marzo, & Isaacs 2003). The list of genes and polymorphisms linked to
PrCa continue to grow.
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Acquired Genetic/Genomic Injuries
Chronic Inflammation
PrCa is a multifactorial disease with many epigenetic risk factors. The following
paragraphs summarize some hypothesis about the epigenetics of PrCa. Inflammation
caused by repeated or chronic infections or inflammatory processes may also contribute
to PrCa (Vasto et al., 2008). One theory is that inflammation may lead to cell DNA
damage, which can initiate or contribute to the cancerous transformation of prostate cells.
Two inherited prostate susceptibility genes, RNASEL and MSR1, may have roles in
response to infections, raising the possibility that prostate infection or inflammation
initiates carcinogenesis in the prostate (Beuten et al., 2010).
Researchers have identified a prostate-cancer-precursor lesion referred to as
proliferative inflammatory atrophy (PIA). Researchers have hypothesized that cells in
PIA give rise to carcinoma by the development of high-grade prostate intraepithelial
neoplasia (HGPIN) (Wang, Bergh, & Damber, 2009). This study found clusters of
atypical epithelial cell hyperplasia (a cell change known to be a precursor to cancer)
inside PIA lesions, particularly in areas of intense focal chronic inflammation. Wang,
Berg, & Damber (2009) concluded that the PIA lesions are the earliest precursor lesions
of HGPIN and PrCa and arise as a consequence of focal chronic inflammation. These
atypical cells may be a consequence of regenerative, proliferation after the activation of
“stem cells” or their progeny by chronic stress (Wang, Berg, & Damber, 2009).
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Geographics
The incidence of and mortality due to PrCa are high in the US and Western
Europe with the highest rates among black men in the United States. Lower rates are
more characteristic of those found in Asia (American Cancer Society, 2010). The risk of
PrCa among Asians increases as they immigrate to North America, implicating
environmental and lifestyle-related factors associated with PrCa in the US (ACS, 2010).
The AfAm Hereditary PrCa study, looking at the linkage of hereditary PrCa to
chromosome 1q24, found that country of origin and racial group affect the incidence and
extent of linkage of PrCa to specific loci.

They found that AfAms families with

hereditary PrCa had >50% linkage on HPC1 (1q24-25) whereas EuAm and French
hereditary PrCa families had 34% and 16% respectively. In the analysis of linkage on
Xq27 loci there was 0% linkage among AfAm families and 15% linkage among EuAm
families. Percentage of linkage was not reported for the French families (Powell et al.,
2001). These findings suggest that the genetic variant contributing to PrCa in EuAms
may be different from the genetic variant causing PrCa in AfAm populations (Powell et
al., 2001).

Diet
One of the most commonly reported environmental factors related to the risk of
PrCa is diet. Cell culture studies have shown that omega-6 fatty acids, found in fat, are
positive stimulants of PrCa growth, while omega-3 fatty acids, found in soy, have a
negative effect (Theodorescu, Mellon & Krupski, 2009). These fats may exert their
effects by alterations of sex hormones, growth factors, or through effects on 5-alpha
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reductase. Steroid 5α-reductase type II (SRD5A2) gene encodes the enzyme responsible
for the conversion of testosterone to the metabolically more active dihydrotestosterone
(Theodorescu, 2009). Soy seems to decrease the growth of PrCa cells in mouse models;
however, apart from epidemiologic factors, no direct evidence supports a beneficial effect
in humans. Soy products have phyto-oestrogens, especially flavonoids, which have a
prophylactic effect on PrCa.

A meta-analysis of studies on soy consumption and

isoflavones in association with PrCa risk found that soy consumption is associated with a
reduction in PrCa risk in men (Yan and Spitznagel, 2009).
A diet high in animal fat may lead to increased risk of PrCa, while a diet rich in
soy may be protective (Yan and Spitznagel, 2009). One suggestion is cooking meat at
high temperatures, as done with charcoal grilling or frying, results in formation of very
potent carcinogens such as heterocyclic amines (Nelson, De Marzo & Isaccs, 2003).
A diet rich in fruits and vegetables may also protect against PrCa. Fruits and
vegetables high in the antioxidant carotenoid lycopene, especially tomatoes, have been
associated with a reduced risk of PrCa. Diets rich in vitamin E may have some protective
effects against PrCa mainly due to the antioxidants found in vitamin E (Gronberg, 2003).
The antioxidant properties of selenium have also been studied and seem to have a
protective effect against PrCa (Crawford, 2003; Gronberg, 2003; Nelson, et al., 2003)
The development of PrCa may also be linked to increased levels of certain
hormones. High levels of androgens, such as testosterone, promote prostate cell growth,
and may contribute to PrCa risk in some men. Insulin-like growth factor (IGF-1) is
another hormone that has been linked to PrCa. Some researchers have noted that men
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with high levels of IGF-1 are more likely to develop PrCa (Crawford, 2003). Tate, Bibb,
& Larcom (2011) examined the effect of estrogens in cow’s milk on PrCa cells and found
that cow’s milk stimulated the growth of PrCa cells in each of 14 separate experiments,
producing an average increase in growth rate of over 30%. Tate, Bibb & Larcom (2011)
concluded that PrCa patients should be educated about the effect of dairy products on
PrCa. Another study found men with diets high in dietary calcium, from milk, cottage
cheese or yogurt, are also at increased risk for PrCa (Gronberg, 2003).

Prostate Cancer (PrCa) in AfAm Men
Researchers from Europe and the US have been studying PrCa since the mid1950s. The increased incidence of PrCa in AfAms has been reported for centuries but the
reason for this ethnic difference is still unclear. One hypothesis of particular interest is
that admixture in AfAms (mainly between European and African) contributes to the
increased incidence of PrCa, considering Africans do not seem to have an increased
incidence of mortality from PrCa (Sekine et al., 2002). A study by the NIH stated that
because of the recent admixture of AfAms (within the last 20 generations), their genomes
have not been shuffled much by recombination since population mixing began (Smith,
2004). Tishkoff et al. (2010) studied 121 African populations, 4 AfAm population and
60 non-African populations for patterns of variation at 1327 nuclear satellite and
insertion/deletion markers.

They found that the ancestry of African-Americans is

predominantly form Niger-Kordofanian (~71%), European (~13%) and other African
(~8%) populations (Tiskhoff et al., 2010).
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Additional hypothesis notes AfAms consume a diet high in animal fat and
genetics is not the source of increased incidence and mortality of PrCa among AfAm
men. Cunningham et al., (2003) used the evidence provided by standardized incidence
ratios (SIRs) in a familial aggregation study to conclude the increased incidence of PrCa
in AfAms when compared with EuAms is not due to racial differences in the prevalence
of germline mutations or other familial factors.

The SIRs for PrCa in first-degree

relatives of AfAm (1.58, 1.05-2.29) and non-AfAm (EuAm and Hispanic Americans)
(1.65, 1.06-2.15) probands are both increased and relatively similar. The researchers
interpreted this to mean that increased incidence of PrCa in AfAms is not due to racial
differences in the prevalence of germline mutations or other familial factors. Kang,
Maygarden, Mohler, & Pruthi (2004), using a retrospective review, compared the clinical
and pathological features in AfAm and EuAm patients with localized PrCa. Their results
indicate that AfAm men do not present at an earlier age and their clinical and
pathological presentation was no different from that of EuAms. This study concluded
that AfAm men do not present with more aggressive PrCa. However, those AfAm men
who carry the highest load of genetic factors are at the highest risk for early
dissemination of disease (Kang et al., 2004).
More recent studies have found evidence that increased incidence of PrCa in
AfAm men is due to variations in polymorphic allelic frequencies, whereas older studies
sought evidence of rare single gene, germline mutations. Rennert, Zeigler-Johnson and
Addya (2011) found an association of susceptibility alleles in the genes ELAC2/HPC2,
RNASEL/HPC1, and MSRI with PrCa severity in EuAm and AfAm men. They found that
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Arg462Gln of the RNASEL/HPC1 gene showed a very strong association with a positive
family history and high-grade prostate tumor. Other studies have also found evidence of
HPC1 as a strong candidate gene for PrCa in the AfAm population (Brown et al., 2004).
RNASEL/HPC1 is thought to be a tumor suppressor gene with functions to regulate cell
proliferation and apoptosis (OMIM). Kittles et al. (2006) concluded that the K1019x
mutation of the EphB2 gene differs in frequency between AfAms and EuAms and this
mutation is associated with increased risk for PrCa in AfAm men with a positive family
history. In an earlier study, Kittles et al. (2001) found that a cytosine nucleotide of the
CYP17 polymorphism was significantly associated with increased PrCa risk and
clinically advanced disease in AfAms. The presence of at least on copy of the C (A2)
allele was significantly higher among AfAm PrCa cases (69%), than among controls
(50%); p- 0.01. Of particular interest, no association was observed with family history
and age at diagnosis and the CYP17 polymorphism (Kittles et al., 2001).
Another possible difference in AfAm men and EuAm men is in hormone levels.
AfAm men have increased levels of testosterone and these higher levels of testosterone
may be related to increased incidence of PrCa (Theodorescu, 2009). Elevated levels of
testosterone are linked with alterations of the AR gene (Hu et al., 2010; Ross et al., 1998).
Elevated levels of testosterone have also been linked to the CYP3A4 gene (Paris et al.,
1999). This study found a positive association between being homozygous for the
CYP3A4 variant in AfAm PrCa patients.

The CYP3A4 genetic variant, a protein

belonging to the cytochrome P450 family, a point mutation of an adenine (A) to guanine
(G) occurs in the 5’ regulatory region of the gene. The protein product of this gene
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oxidizes testosterone, which might also deactivate the hormone, although this is yet to be
proven. As a result men carrying the CYP3A4 variant allele may have more testosterone
available to be converted to dihydrotestosterone, which is the main male sex hormone
that regulates prostate cell division (Paris, et al., 1999).

Conclusion
There are multiple clinical and public health implications of family history as a
predictor of genetic predisposition to PrCa. Firstly, the empiric risk for the first-degree
relative of a man with PrCa is 2 to3-fold compared to the lifetime risk of patients with no
family history of disease (Carter, et al, 1993). Use of a family health history can target
persons with a family history and elevated risk of developing PrCa, but the goal of such
knowledge is to empower men, not cripple them with fear and anxiety. Educating at-risk
individuals about lifestyle changes can promote health and prevent disease, make at-risk
men better consumers of healthcare, better promoters of their personal health and the
health of their family. The key to decreasing health disparity related to any disease is
education. Education empowers at-risk individuals with information needed to prevent
disease and promote overall health.
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CHAPTER V
SUMMARY AND CONCLUSION

Summary
The public health burden of Prostate Cancer (PrCa) for African-American
(AfAm) men is substantial. AfAm have the highest incidence rate for PrCa in the United
States and are more than twice as likely as European-American (EuAm) men to die of the
malignancy. The incidence rate for AfAm men is 255.5 and the mortality rate is 62.3
compared to EuAm men with an incidence rate of 161.4 and mortality rate of 25.6 (NCI,
2008). This dissertation reviews the literature, describes the use of the ACCE model to
test clinical validity of a tool used to identify incidence of inherited PrCa in AfAm males
and analyze a case report which focuses on a family with multiple members with a PrCa
diagnoses.
The review of the literature concluded that the analytical validity of self-reported
family history is strong. Family history of PrCa is usually accurate and the effect of
recall bias is minimal. There is some question as to the accuracy of family history as
reported by AfAm men. The one study comprised of an AfAm sample, found that 48%
of AfAm changed their family history when surveyed a year later (Weinrich, FaisonSmith, Hudson-Priest, Royal & Powell, 2002). The literature for clinical validity and
clinical utility related to family history of hereditary prostate cancer is inconclusive, due
to the lack of a genetic test to confirm that men with pedigrees that indicate hereditary
PrCa, actually harbor the same causative genotype. There were no empirical studies that
examined the ethical, legal, and social implications of family history of hereditary PrCa.
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The gray literature that was reviewed focused on general ethical, legal and social issues
related to the family history of inherited disorders in general with the greatest implication
being the risk for breach of confidentiality and discrimination.
The clinical validity portion of the ACCE model guided the evaluation of the
piloted family history tool and pedigree analysis method. In the pilot study eleven
participants reported a personal family history of cancer. One hereditary PrCa family
was identified in the sample (N=49) and age was the only statistically detectable predictor
of a personal history of PrCa (Likelihood Ratio Chi Square (χ2) = 10.193, p = 0.001).
Two other predictor variables, number of brothers with PrCa and having a brother with
PrCa approached significance (Likelihood ratio = 2.892, p = 0.089 and 6.711, p = 0.082)
respectively. Seven of the eleven participants that reported a personal history provided
authorization for release of health information for the South Carolina Cancer Registry
(SCCCR). Four of the seven (57%) personal histories were linked positively to the
SCCCR database.
The case report reveals the visual impact of the pedigree, developed form the
family history data, facilitating the identification of possible Mendelian patterns of
inheritance. More importantly the pedigree facilitates the identification of the at risk
individuals. The at risk individuals that are the focus of targeted health promotion and
early screening programs.

Conclusion
This pilot study is the foundation for future research of genetic and genomic
influences of PrCa disparity in AfAm males. The small sample size was a significant
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limitation of the pilot study, but statistical evidence of age as a predictor of PrCa and the
near significance of other known predictors support the analytical validity of the piloted
family history tool and pedigree analysis method. According to the National Cancer
Institute (2012) 5-10% of the total cases of PrCa in the general population are hereditary
PrCa. Therefore, it was expected that out of 11 cases of PrCa there would be one case of
hereditary PrCa. In this study sample of 11 cases, one participant met the criteria for
hereditary PrCa. In addition the nearly parallel alignment of the age related incidence
potentially indicates that the selected rural southern population is affected with PrCa in a
manner that closely mimics that of the state and nation. The investigator anticipates that
improved design and statistical analysis will help to determine if the peak of incidence
between the ages of 45-65 years in the pilot sample is an indication of potential
hereditary PrCa or just a chance finding due to small sample size. Finally, the novice
investigator is also interested in gaining more experience with implementation of the
ACCE model, in anticipation of a genetic test for hereditary prostate cancer in the very
near future.
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Appendix A
Common Genetic Terms Used Throughout Manuscript
Term
Allele
African-American (AfAm)

European American (EuAm)

Genome wide linkage scan
Genome wide association
studies

Mapping linkage analysis

Loss of heterozygosity

Definition
An alternative or variable form of a gene at a specific
chromosome location
“The term AfAm refers to a person of African
ancestral origins who self identifies or is identified by
others as AfAm. While the term AfAm has been used
at least since the 1920s, it has been the preferred term
in the USA since the 1970s. As most AfAms in the
USA originated from sub-Saharan Africa, the term is
not applied to Africans from northern African
countries such as Morocco. Most AfAms are
descendants of persons brought to the Americas as
slaves between the 17th and 19th century (distant
ancestry). Such people differ from others who came
from Africa or the Caribbean in the 20th and 21st
centuries (recent ancestry) in terms of culture,
language, migration history, and health. These
differences are often ignored” (Agyemang, Bhopal,
and Bruijnzeels, 2005, p. 1016).
“EuAms are the most populous single ethnic group in
the US according to United State census categories.
EuAms are usually treated as a single population and
the use of labels such as “white” or ‘Caucasian’ can
propagate the illusion of genetic homogeneity.
However, EuAms in fact form a structured population,
due to historical immigration from diverse source
populations” (Price et al., 2008, p. e236).
A scan of the genomes of thousands of individuals
from a particular population who have a particular
phenotype for single nucleotide polymorphisms that
they share, but are much rarer in people who do not
have the trait.
Uses family pedigrees to follow the inheritance of a
disorder over a few generations by looking for
consistent, repeated inheritance of a particular region
of the genome in family members with the disorder.
When an individual goes from having one mutated
allele and one wild allele to having two mutated
alleles.
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Germline mutation
Single nucleotide
polymorphisms
Epigenetic
Homeodomain containing
transcription factor
Proband
Consultand
Admixture

A mutation in the germ cells (sperm and ova) and can
be passed on to one’s children at conception.
A type of point mutation inherited in a gene that alters
gene activity in a certain percentage of the general
population.
Biochemical factors that alter gene expression but do
not involve changes in the DNA sequence.
A cluster of genes that encode transcription factors
containing DNA-binding domain of approximately 60
amino acids.
An affected family member coming to medical
attention independent of other family members.
Individual(s) seeking genetic counseling/testing.
A measure of the proportion of different ancestral
genetic contribution found in an individual.
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studies. PLoS Genetics, 4, 0009-0017.
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Family History Tool and Demographic Form
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Appendix C
Dissertation Research/Recruitment Contact Log

Date
7/25/11
8/12/11
8/18/11
9/13/11

9/15/11
9/22/11

9/19/11
10/3/11
10/9 /11

10/10/11

10/12/11

10/13/11

10/13/11
10/13/11

Purpose of Contact
Agency/Institution
Collaboration with UsToo-Greenville Chapter
UsToo
Collaboration
Breast and Prostate Awareness Forum
Greenville West End community
Collaboration
SCCA-Prostate Work Group
Attempt to
Anderson Ministerial Organization
establish contact
Scheduled for 10/25/11
with churches
Collaboration
Prostate Screening Panel-Russell House USCColumbia
CollaborationSCCCR
guidance in
completing
application
1st letter went out
NA
to churches
No response from
letters
Attempt to
Provided contact information for Tumbling Shoals
establish contact
Baptist Association (Guy Sullivan)
with churches
Attempt to
Moderator of Tumbling Shoals Baptist Association
establish contact
with churches
Attempt to
Provided contact for Rocky River Baptist
establish contact
Association
with churches
(Donald R. Owens)
Attempt to
Unable to contact Mr. Owens
establish contact
with churches
Schedule
Scheduled presentation at Popular Springs AME for
Presentation
Oct 26th at 7:00 pm (Laurens)
Attempt to
Unit 1- Rocky River Baptist Association
establish contact
On agenda for 10/29/11 at King David Baptist
with churches
Church
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Date
10/24/12

10/25/11

10/26/11
12/22/11

1/3/12

1/3/12

2/5/12
2/11/12

1/19/121/24/12
3/18/12
3/25/12
4/1/12
4/15/12
4/29/12

Purpose of Contact
Attempt to
establish contact
with churches
Attempt to
establish contact
with churches
Presentation
Attempt to
establish contact
with churches
Attempt to
establish contact
with churches
Attempt to
establish contact
with churches
Presentation
Attempt to
establish contact
with churches
Presentation
Presentation
Presentation
Presentation
Presentation
Presentation

Agency/Institution
Tumbling Shoals
(5 attendees)
7:00 pm
Anderson Ministerial Alliance
12:00 pm
(4 attendees)
Popular Springs AME
Johnny Payne also presented with me
Welfare Baptist Church

Mt Herman Baptist Church
Scheduled for 2/5/2012
Rocky River Baptist Association
Scheduled time on agenda for 2/11/12
Mt. Herman Baptist Church
20 attendees
Rocky River Baptist Church Mid-Winter Session

School of Methods
New Holly Light (9:00 am)
Mt Moriah Baptist Church (11:00 am)
Mt. Zion Baptist Church (11:00 am)
Mt. Pleasant Baptist Church (11:00 am)
Generostee Baptist Church (10:45 am)
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Appendix D
IRB Approval Letter
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Appendix E
IRB Information Letter
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Appendix F
Authorization for Release of Protected Health Information
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Appendix G
South Carolina Central Cancer Registry Statistics Fee Waiver
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Appendix H
Discovering History Education Workshop Presentation Documents
Discovering HIStory Abbreviated Presentation

Discovering HIStory Full Presentation
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Appendix I
Clemson University Healthcare Genetics Toolkit
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